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Abstract approved: 
This thesis describes a project to produce controlled release ketoprofen 
beads for capsules, both at Oregon State University and in an industrial scale-up 
operation, that are bioequivalent to the commercial product Oruvail. A bead 
formulation was produced by layering drug and binders in water onto nonpareil 
sugar seeds in a spray coating apparatus. Ketoprofen beads manufactured in this 
manner will immediately release their drug content in either an in vitro or an in 
vivo environment. Industrially produced beads were non-homogeneous in size. 
Large beads in a coating batch sweep up a disproportional amount of coating 
material leading to a thicker coating layer and decreased drug release rates.  In 
order to predict the effects of coating modifications, an equation was developed to 
accurately predict the coating thickness of any material applied to spherical 
particles of any size. The equation developed is suggested as a replacement for 
one that has been in published and cited for over 20 years, but overestimates 
coating thickness. 
Redacted for PrivacyThe bulk of this thesis details the process of altering the drug release 
characteristics of the beads through application of diffusional and enteric barrier 
coatings, and testing for bioequivalence with Oruvail through biostudy data 
gathered from human volunteers. Urinary drug excretion rates were measured as a 
substitute for timed blood sampling of the subjects.  Validity of the substitution 
was shown. Fed state biostudies involved beads manufactured and coated at 
Oregon State University. Fasted state biostudies involved beads that were 
industrially manufactured in a scale-up operation and coated both industrially and 
at Oregon State University. 
Deconvolution, a mathematical tool, was used to determine in vivo 
dissolution rates and the need for further coating modification.  Statistical testing 
using a Two 1-Sided T test was the final arbiter of whether or not bioequivalence 
was concluded. Bioequivalence was achieved in subjects under a fed state and 
finally under fasting conditions, as required by the Food and Drug Administration, 
with drug beads coated with ethylcellulose to slow drug release and overcoated 
with an enteric bather to retard early drug release. 
Deconvolved in vivo dissolutions originating from biostudy data were 
used to develop In Vitro / In Vivo Correlations (IVIVC's). IVIVC's were used to 
predict in vivo biostudy data from in vitro dissolution results following coating 
formulation modification. A practical guide for the development and use of an 
IVIVC was written for pharmaceutics practitioners who have an understanding of 
pharmacokinetics, but may lack sufficient expertise in pharmacokinetics to develop 
an IVIVC. Bioequivalence Studies of Ketoprofen: 
Product Formulation, Pharmacolcinetics, Deconvolution, 
and In Vitro  In Vivo Correlations. 
by 
Kris Edward Holt 
A THESIS
 
submitted to
 
Oregon State University
 
In partial fulfillment of 
the requirements for the 
degree of 
Doctor of Philosophy 
Completed August 20, 1997
 
Commencement June 1998
 Doctor of Philosophy thesis of Kris Edward Holt presented on 
August 20. 1997 
APPROVED
 
rofessor, Representing Phar 
Dean of College of Pharmacy 
Dean of Graluate School 
I understand that my thesis will become part of the permanent collection of Oregon 
State University libraries. My Signature below authorizes release of my thesis to 
any reader upon request. 
Kris Edward Holt, Author 
Redacted for Privacy
Redacted for Privacy
Redacted for Privacy
Redacted for PrivacyTABLE OF CONTENTS  Page 
Introduction  1
 
Chapter 1:  Deconvolution in Sustained-Release Formulations  3
 
Abstract  4
 
Introduction  5
 
Materials and Methods  6
 
Results and Discussion  14
 
Conclusions  37
 
References  38
 
Chapter 2:  Predictive Equation for Polymer Film-Coat Thickness
 
on Spherical Particles  39
 
Abstract  40
 
Introduction  41
 
Materials and Methods  42
 
Results and Discussion  49
 
Conclusions  59
 
References  60
 TABLE OF CONTENTS (continued)  Page 
Chapter 3:  Formulation of Ketoprofen Beads Bioequivalent to 
61 Oruvail 
62 Abstract 
63 Introduction 
64 Materials and Methods 
70 Results and Discussion 
90 Conclusions 
91 References 
Chapter 4:  In Vitro  In Vivo Correlations and Convolution; A 
92 Practical Guide 
93 Abstract 
93 Introduction 
94 Results and Discussion 
116 References 
117 Bibliography Figure  LIST OF FIGURES  Page 
1.01  Comparison of mean ketoprofen excretion rate data to 
published blood concentrations following ingestion of 
Oruvail  15 
1.02  Dissolution of Oruvail 
200mg strengths 
comparison of 100, 150, and 
16 
1.03  Dissolution of ketoprofen-layered beads coated with 
various amounts of ethylcellulose  18 
1.04  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking 4% ethylcellulose coated ketoprofen 
beads  19 
1.05  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking 6% ethylcellulose coated ketoprofen 
beads  20 
1.06  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking 8% ethylcellulose coated ketoprofen 
beads  21 
1.07  Deconvolved GI absorbance of ketoprofen from ketoprofen 
beads coated with 4, 6, and 8% ethylcellulose  24 
1.08  Dissolution of enteric over ethylcellulose coated ketoprofen 
beads  25 
1.09  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking ketoprofen beads coated with 4% 
ethylcellulose and overcoated with a 5% enteric coat  27 
1.10  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking ketoprofen beads coated with 4% 
ethylcellulose and overcoated with a 10% enteric coat  28 
1.11  Deconvolved GI absorbance of ketoprofen from ketoprofen 
beads layered with enteric over ethylcellulose coatings  30 
1.12  Dissolution of ethylcellulose over enteric coated ketoprofen 
beads  32 
1.13  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking ketoprofen beads coated with a 4% 
enteric coat and overcoated with 5% ethylcellulose  33 
1.14  Deconvolved GI absorbance of ketoprofen from ketoprofen 
beads layered with ethylcellulose over enteric coatings  36 Figure  LIST OF FIGURES (continued)  Page 
2.01  Calculated film-coat thickness for applications of 0-15% 
coating material on beads 0.3-4.0mm in diameter  48 
2.02  Measured film thickness from SEM micrographs compared 
to predicted 0. Beads produced and coated in laboratory 
equipment  51 
2.03  Measured film thickness from SEM micrographs compared 
to predicted 0. Beads produced and coated in industrial 
equipment  53 
2.04  Dissolution of ketoprofen from ethylcellulose-coated beads. 
Comparison of homogeneous beads versus non­
homogeneous beads  57 
3.01  Comparison of mean ketoprofen excretion rate data to 
published blood concentrations following ingestion of 
Oruvail  71 
3.02  Dissolution of Oruvail 
200mg strengths 
comparison of 100, 150, and 
72 
3.03  Mean ketoprofen excretion rates of subjects taking Oruvail 
under fed and fasted conditions  74 
3.04  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking beads coated with a 4% enteric coat 
and overcoated with 5% ethylcellulose  75 
3.05  Deconvolved GI absorbance of ketoprofen from Oruvail 
versus beads coated with 4% enteric coat and overcoated 
with 3% ethylcellulose  77 
3.06  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking beads coated with a 4% enteric coat 
and overcoated with 3% ethylcellulose  79 
3.07  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking beads coated with a 4% enteric coat 
and overcoated with 5% ethylcellulose  81 
3.08  Deconvolved GI absorbance of ketoprofen from Oruvail 
versus beads coated with 4% enteric coat and overcoated 
with 5% ethylcellulose  82 
3.09  Dissolution of ethylcellulose- coated industrially produced 
beads  84 Figure  LIST OF FIGURES (continued)  Page 
3.10  Dissolution of 5A/IND beads overcoated with various 
weight of methacrylate  85 
3.11  Deconvolved GI absorbance of ketoprofen from Oruvail 
versus beads coated with 5% ethylcellulose and overcoated 
with a 6% enteric coat  87 
3.12  Mean ketoprofen excretion rates of subjects taking Oruvail 
versus those taking beads coated with 5% ethylcellulose 
and overcoated with a 6% enteric coat  88 
4.01  Dissolution profiles for formulations of controlled release 
ketoprofen  96 
4.02  Average urinary excretion rate of ketoprofen for fasted 
subjects ingesting immediate and controlled release 
formulations 
99 
4.03  Average urinary ketoprofen excretion rate following fasted 
administration of a 75mg IR dose  103 
4.04  Deconvolved input functions from biostudy data for 
controlled release ketoprofen formulations  105 
4.05  IVIVC's for controlled release ketoprofen formulations  107 
4.06  Dissolution time-scaled IVIVC's for controlled release 
ketoprofen formulations 
109 
4.07  Dissolution time-scaled IVIVC's for controlled release 
ketoprofen formulations; effect of scaling intestinal fluid 
dissolution time 
110 
4.08  Graphical representation of convolution  112 
4.09  Incremental drug input from the input function  114 
4.10  Superposition of input responses arising from incremental 
inputs  115 Table  LIST OF TABLES	  Page 
1.1  Means and Statistics: Ethylcellulose Coatings	  22
 
1.2  Means and Statistics: Enteric over Ethylcellulose Coatings  29
 
1.3	  Means and Statistics; Ethylcellulose over Enteric Coatings  34
 
2.1	  Comparison of Film Thickness Calculated by Two  46
 
Methods
 
2.2	  Characteristics of Industrially Produced Beads  55
 
3.1	  Characteristics of IN) Beads  66
 
3.2	  Means and Statistics; Ethylcellulose over Enteric Coatings  78
 BIOEQUIVALENCE STUDIES OF KETOPROFEN:
 
PRODUCT FORMULATION, PHARMACOKINETICS, DECONVOLUTION,
 
AND IN VITRO - IN VIVO CORRELATIONS
 
INTRODUCTION 
Development of a controlled release drug formulation is often a process of 
trial and error.  Typically, one formulates an array of products with clustered 
release properties. Selection of one of the formulations for biostudies is based on 
in vitro evidence of drug release characteristics. However, in vitro techniques 
rarely predict in vivo drug release patterns without prior correlation to biostudy 
data. 
Chapter 1 of the thesis describes formulation, coating, in vitro release, and 
in vivo biostudies of ketoprofen beads for capsules towards bioequivalence with 
Oruvail, a commercial product. Beads were manufactured by spray layering drug 
and binders in water onto nonpareil sugar seeds. After coating, dissolution studies 
were used to select formulations for biostudies under fed conditions in human 
subjects. Deconvolution of biostudy data was used to determine the need for 
coating modifications and subsequent biostudies. 
Chapter 2 presents a novel equation for the prediction of film coat thickness 
of any material applied to any size spherical particle. The film thickness equation 
takes into account the effects of particle radius and density, and the density and 
amount of coating material to be applied. An application is presented for 
calculation of amount of coating material to be applied to a bead batch to yield an identically thick polymer layer which is pre-requisite for bioequivalent drug release 
from bead batches with differing diameters. 
Chapter 3 details the process of achieving bioequivalence to Oruvail of an 
industrially scaled up production of ketoprofen beads. Biostudies were conducted 
as before, but in a fasted state. 
Chapter 4 is a practical guide for the development and use of an In Vitro I 
In Vivo Correlation in the formulation of products to be bioequivalent to a 
commercial standard. 3 
CHAPTER 1
 
DECONVOLUTION IN SUSTAINED-RELEASE FORMULATION 
by Kris E. Holt and James W Ayres 4 
ABSTRACT
 
An in vitro  in vivo correlation method is utilized for optimizing drug release rates 
from solid oral sustained-release formulations. Deconvolution of urinary drug 
excretion rate data provides a rapid, non-invasive method of assessing effects of 
modifications in developmental drug formulations. The method requires no blood-
draws and is applicable to all drugs that are extensively excreted through renal 
filtration as either parent drug or metabolite. Ketoprofen served as the model drug 
and was spray-layered, with binders, onto nonpareils to a loading of 88% w/w. 
Drug beads coated at 4% or 6% weight gain with ethylcellulose were chosen for 
initial biostudy based on similarity of drug release rates compared to a commercial 
standard. Ketoprofen excretion rate data for the commercial standard are shown to 
coincide well with scaled blood concentration data. Deconvolved biostudy data 
indicated need for an enteric coated formulation. Two methods of enteric coating 
were studied (external and internal) and bioequivalence to reference was achieved 
with 5% methacrylic acid copolymer, type C, over 4% ethylcellulose. 
KEY WORDS: deconvolution; in vitro - in vivo correlation; drug excretion; 
formulation modification; bioequivalence study; ketoprofen. 5 
INTRODUCTION
 
Development of a new controlled or extended release drug formulation is 
often a process of trial and error. Prior experience with the excipients to be used 
and awareness of desired drug release characteristics leads to formulation of an 
array of products with clustered release properties.  Selection of formulations for 
biostudies or evidence of the need for further modification is based on in vitro drug 
release characterization. However, in vitro techniques rarely predict in vivo drug 
release patterns without prior correlation to biostudy data. 
Standard in vivo sampling requires timed blood draws for analysis of 
circulating drug concentrations. Blood sampling of human subjects is undesirable, 
at least in the initial stages of formulation development, because of discomfort, 
expectation of recompense, and the possible communication of blood-borne 
diseases.  Analysis of drugs in urine is non-invasive in that no penetrative 
procedures are used for sampling. 
Since drug excretion rates in urine have been shown to parallel serum drug 
concentrations, analysis of drug excretion gives evidence of in vivo performance of 
test formulations. Thus, analysis of urinary excretion data are useful in developing 
new product formulations. This is especially true for older, established drugs 
where pharmacokinetic data and drug concentrations in blood have already been 
published and are available for comparison to urinary excretion rate data. This 
paper details formulation modification based on in vivo input functions for test 
formulations determined by deconvolution of excretion rate data. In vivo input 6 
functions and their correlations to in vitro dissolution are used to modify a drug 
formulation towards a desired release pattern. A specific case history is presented 
for development of a controlled release NSAID, but the technique is applicable to 
any model drug that is extensively excreted through renal filtration as either parent 
drug or metabolite. 
MATERIALS AND METHODS 
Materials 
Ketoprofen was chosen as the model drug for this report. The commercial 
reference used was Oruvail, produced by Wyeth-Ayerst. Ketoprofen, 
hydroxypropylcellulose (Klucel EF), polyvinylpyrrolidone K-30 (PVP), dibutyl 
sebacate (DBS), triethyl citrate ('1 'EC), talc, and polysorbate 80 were all either 
USP/NF or reagent grade. Ethylcellulose-coat working solutions for spray 
application contained 100g Aquacoat (FMC), 100g water, and 6.7g each of DBS 
and TEC. Enteric-coat working solutions for spray application contained 100g 
Eudragit L30D-55 (Rhom Pharma), 3g DBS, 7g talc, 0.2g polysorbate 80, and 
89.8g water. 
Product formulation 
Drug formulations were manufactured at Oregon State University by spray-
layering to produce beads for inclusion in capsules. Drug was suspended in a 
solution of binders to a 20% solids concentration and layered onto nonpareil sugar 7 
seeds using a bottom-spray coating chamber with Wurster column insert mounted 
on a fluid-bed dryer. In this manner, formulation beads were built up in four 
successive layers of 600g ketoprofen, 15g Klucel, and 30g PVP, applied to an 
initial charge of 600g 50 mesh nonpareil seeds. After each application, all product 
was removed, weighed, and 600g was returned to be layered with the next 
application. The first division of the batch contained 600g of 48.2% ketoprofen; 
the second was 600g of 71.4% drug; third was 82.6% drug. The fourth layer 
application produced 1.2kg of 88.0% ketoprofen, the balance being the sugar core 
and binders. Final beads produced were homogeneous in size; approximately 
1.5mm in diameter. After spray-coating with polymers at various levels, each 
formulation was subjected to in vitro testing. 
Dissolution 
Dissolution, following USP Method 2, began in simulated gastric fluid (pH 
1.4; no enzymes) stirred at 50 rpm. After 2 hours gastric pretreatment, 
formulations were filtered from the media by vacuum aspiration through Whatmann 
#1 paper. Dissolution continued immediately in simulated intestinal fluid (SIF, pH 
7.4; no enzymes) by dipping the filter paper into the SIF to wash off gross 
particles, tearing the paper into quarters, and adding the paper to the dissolution 
vessel to include any fine particles of retained formulation. Samples were 
collected, with replacement, at 0.5, 1.0, 1.5, and 2.0 hours during the gastric 
pretreatment and at 0.25, 0.5,  0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 20 hours during 
SIF dissolution. 8 
Samples were diluted 1:10 (1 nil plus 9 nil diluent) with SIF and analyzed 
at 254nm. Known concentrations of drug were prepared for standard curves in the 
range of 0 to 25 µg /m1 of ketoprofen in SIR Candidate formulations that gave 
drug dissolution similar to a desired drug release pattern were selected for in vivo 
testing. 
Urinalysis 
In vivo testing of formulations used human volunteers in a cross-over 
design. Subjects fasted overnight and provided a zero-time urine sample prior to 
dosing. Subjects were asked to consume a standardized breakfast of 1 cup (8oz) 
2% milk and 2 slices of dry toast, then ingest a formulation. Subjects collected the 
contents of their bladders in 24oz Whirl-Pak bags at scheduled sampling times. 
Caffeineated beverages were withheld for 2 hours post-dosing, but water was 
allowed ad lib. Target sampling times were 0-12 hours post-dose in 1 hr 
increments, and at 16, 24, 28, 32, and 36 hrs. 
Drug concentrations prepared for standard curves, made by dilution with 
blank urine of a stock solution of 1000Ag ketoprofen per milliliter in blank urine, 
range from 2/4/m1 to 300/4/ml. Standards were treated the same as all other 
urine samples during the analysis procedure. Volume and time elapsed since drug 
ingestion were recorded for each urine sample and a portion was saved for drug 
concentration measurement. Assay procedure was modified from that of Upton(1) 
to avoid inclusion of phosphates in sample and mobile phase. Aliquots (1000) of 
each of the samples or standards were mixed with 1 ml of diluent and 100;41 1M 9 
NaOH in a plastic test tube. Sample diluent was 63mg naproxen internal standard 
in 250m1 75% Me0H that was re-diluted with 3 parts water prior to use. Tubes 
were vortexed and set aside at room temperature for 15 minutes to effect 
hydrolysis (pH 12) of any glucuronide ketoprofen metabolites. Samples were 
acidified (pH 1) with 125A1 concentrated HC1 and vortexed to convert sodium salts 
of ketoprofen to the un-ionized form. After addition of 2m1 ether, samples were 
capped, shaken, and then centrifuged at 3000 rpm for 5 minutes to separate the 
liquid phases. The organic phase was transferred to fresh tubes and dried under 
vacuum. 
Mobile phase for HPLC analysis was 43% acetonitrile plus 4m1 glacial 
acetic acid per liter of solution. Dried sample extracts were dissolved in 3001L1 
mobile phase and vortexed. HPLC proceeded at lml/min flow rate through a 51.4, 
100A C18 0.46 x 1.5cm guard column and 5g, 100A C18 0.46 x 25cm analytical 
column (Microsorb-MV, Rainin). Absorbance was monitored at 254nm. 
Ketoprofen elutes first at 9 minutes after injection, with naproxen internal standard 
following at 11 minutes. 
Deconvolution 
It is often advantageous to be able to predict drug absorption patterns from 
in vitro dissolution data for oral controlled release products(2). This is especially 
true when developing new formulations to be bioequivalent to an established 
reference product. The mathematical processes employed to find the desired 
relationships are called deconvolution and convolution(3). If a relationship 10 
between drug input and a measurable response has the properties of linearity 
(double dose produces double response) and time invariance (identical incremental 
doses at time = 0 and time = t produce identical responses offset by time = t), 
then the following are defined(4): 
Input rate = f(t) = Function for rate of drug delivery to the reference site 
(where response is to be measured). Input can be constant, variable, or 
discontinuous. 
Response = C(t) = Function for any measurable quantity that is a direct result 
of input. Examples include plasma concentration, excretion rate, writhing, 
pulse rate, blood pressure, .... 
Unit impulse = 45 = Unit dose of any amplitude (no limit on amount of drug 
input) and zero duration (no time lag; instantaneous absorption and 
distribution) such that the integral of b(t) equals one. Closest approximation 
is an IV bolus of one unit of drug. 
Unit impulse response = C8 = Time course of response change following unit 
impulse. An example is the elimination function for plasma drug 
concentration as a response to an IV bolus of one unit of drug. Function is 
unique for each drug and subject combination and has units of (response 
function units/ input function units). 
Impulse response = Co(t) = Function that describes the cumulative effects of 
response changes, following all previous drug input f(to ), at time = t. 
Consider input as a series of successive instantaneous impulses. Then the 
incremental amount of drug delivered at time = ii, is f(rOzir = (rate of drug input 11 
at time T)*(time increment). Response at time = t is the sum of the products of 
incremental input (impulse) and associated impulse response: 
n=nT 
/MX
c(t) = E pr,)co(t  tn)AT 
n=0 
When AT approaches 0, then the relationship between input and response may be 
described according to the convolution integral: 
c(t) = (ca *.n(t) =  fotc6(t -TAT)cbr 
Deconvolution is a process of solving the convolution integral for either input rate 
of drug [f(t)] or impulse response [co(t)] when one or the other is known and the 
response to input [c(t)] is also known. Usually,  deconvolution is used to solve for 
input rate in order to characterize the rate of drug absorption, especially when oral 
controlled release dosage forms are involved. This approach allows comparison of 
the absorption rate portion of bioavailability for formulations given by the same 
route of administration. Functions used in deconvolution for this report are as 
follows: 
Response = c(t) = Function which describes the time-course of urinary 
excretion rate of drug for the oral controlled release product being 
evaluated. Response function in this report is urinary excretion rate (or 
dU/dt) of ketoprofen following oral formulation administration. 
Input rate = f(t) = Function which describes the time-course of in vivo
 
absorption rate of drug from the GI tract. For controlled release
 
formulations, under an assumption that absorption is dissolution rate
 12 
limited, input is also the in vivo dissolution rate function. Bioequivalent 
formulations have equivalent input rate functions. 
Impulse response = cb = Function that describes the time-course of change in 
urinary excretion rate of drug following an IV bolus dose. Impulse 
response was approximated by a mono-exponential function with a 
literature-derived elimination rate constant as the exponential factor. 
Integration of in vivo absorption rate functions obtained from deconvolution 
give cumulative amounts of drug absorbed, which is in vivo dissolution when 
absorption is dissolution rate limited. Cumulative amount dissolved in vivo versus 
time is referred to as input function in this report. Input functions generated can 
be used to develop in vitro / in vivo dissolution (i.e., in vitro dissolution versus in 
vivo absorption) correlations. Deconvolved input functions from different 
controlled release formulations can be rapidly compared by visual inspection for 
relative equivalence of rates and extents of in vivo dissolution. Convolution is then 
used to predict in vivo excretion rate data from in vitro dissolution data without 
further in vivo study. 
Conventions 
Coatings were applied as a w/w increase to ketoprofen beads. Hence, 5% 
Aquacoat indicates a 5g weight gain to 100g nude drug-layered beads. This 
formulation would be designated 5A in this report. Multiple layers are read as 
exterior to interior; 5E/5A indicates 5g Eudragit over 100g of 5A beads. 13 
Since urinary excretion was followed in the course of this study, C. 
corresponds to the maximum excretion rate; T. to the time of maximum excretion 
rate; and AUC to the area under the excretion rate versus time curve. The 
subscripts R and T refer to the Reference (Oruvail) and Test formulations. All 
statistical results reported are for comparison of a new Test formulation parameter 
to that of Oruvail (reference standard). 
Statistics 
Two sets of statistics are reported: a two-sided Student t test at a=0.05 on 
the null hypothesis Ho: AT  = 0 and the two one-sided t test(5) at a=0.10 on the 
null hypotheses Ho,: 1.1..r<0.8pR and H02: ikr > 1 . 2AR .  Interpretation of results is 
given as follows: 
Two-sided t test (2STT): Acceptance of the null hypothesis (Ho) indicates 
that there is not enough evidence to conclude a significant difference exists 
between the parameter mean of the Test formulation and the corresponding 
parameter mean of the Reference; i.e., the parameters are equivalent. Rejection of 
the null hypothesis is a strong indication of non-bioequivalence for the two 
formulations. 
Two one-sided t test (2-1STT): Acceptance of either of the two hypotheses 
indicates that there is not enough evidence to exclude the possibility that ps is 
higher or lower than pR+20%, respectively, which are the criteria for 
bioequivalence. Bioequivalence can only be concluded when both null hypotheses 14 
are rejected. Therefore, acceptance of one or both null hypotheses is defined as 
non-bioequivalence. 
RESULTS AND DISCUSSION 
Introduction 
Biostudy data collected for this report result from ingestion of a formulation 
after consumption of a standardized breakfast. Later biostudies, not detailed here, 
under fasting conditions gave urinary excretion rate data that coincided well with 
scaled ketoprofen blood concentration data given in the Oruvail product insert 
(figure 1.01). Data from a second report of average Oruvail blood concentrations 
versus time(6) is given as a comparison. Urinary excretion rates are expected to 
parallel plasma drug concentrations, and results in figure 1.01 are good 
confirmation that urinary excretion rates can be used in preliminary bioavailability 
comparisons. 
Oruvail is available in three strengths: 100, 150 and 200mg. Analysis of 
fill-volumes and dissolution results (figure 1.02) indicates that all three strengths 
are varying amounts of the same formulation. Guidances for controlled release 
dosage forms(7,8) indicate that bioequivalence need be established only for the 
highest strength capsule when dosage strength is dependent solely on amount of 
formulation present. c..4`  20  5 
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Figure 1.01: Comparison of mean ketoprofen excretion rate data to published concentrations following ingestion of Oruvail 120 
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Figure 1.02: Dissolution of Oruvail -- comparison of 100, 150,and 200mg strengths 
:D, 17 
Ethylcellulose Coatings 
In the first iteration of product formulation, only a pH-independent 
diffusional resistance membrane was used to control drug release. Figure 1.03 
shows dissolution results for ketoprofen-layered beads coated with 1-10% 
ethylcellulose. Beads with 4% and 6% ethylcellulose coats (4A and 6A) were 
chosen for an initial biostudy based on in vitro release patterns similar to that of 
the reference. Urinary excretion rate data are presented in figures 1.04 (4A) and 
1.05 (6A) versus the reference formulation. Du/dt data were also gathered for 8A 
(figure 1.06) to develop correlations between coating percentage and in vivo input 
rates.  Statistical analysis of average dU/dt data (table 1.1) reveals bioequivalence 
of 4A based on a 2STT; 6A fails in a test of AUC; 8A fails for both AUC and 
C.. All formulations fail a 2-1STT of bioequivalence. The number of test 
subjects is very low in these preliminary trials, and statistical data are therefore of 
very limited value. However, the general shapes and trends of data in figures 4-6 
are of great value in guiding formulation changes, and these date were relatively 
quick and easy to collect. "a 
250 
E 
nti 200 
a) 
0
2 150 
6  6 5A
to 
100  e 1A & 6A 
Q  .... 2A  0. 8A 
13-- 3A . 10A 50 
--III 4A  Oruvail 
I 
o  . IIIIIIIIIIIIIII 
5  10  15 20  25 
Time (in hours) 
Figure 1.03: Dissolution of ketoprofen-layered beads coated with various amounts of ethylcellulose Oruvail Mean (+/-SD) 
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Figure 1.04: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking 4% ethylcellulose coated ketoprofen beads T.N., 20 
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Figure 1.05: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking 6% ethylcellulose coated ketoprofen beads Oruvail Mean (+/-SD) 
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Figure 1.06: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking 8% ethylcellulose coated ketoprofen beads 22 
4A  6A  8A  Oruvail 
AUC  119.71  98.15  67.43  131.61
 
( ±SD)  (16.41)  (15.69)  (25.54)  (15.15)
 
Na  3  2  2  4 
2STT'  0.995  *2.5270  *4.048* 
2-1STP LOW  1.205  -0.539  -2.388 
2-1STT HIGH  *3.194*  *4.516*  *5.708* 
C.  9.76  6.75  5.19  11.81
 
(±SD)  (2.51)  (0.74)  (0.69)  ( 3.61)
 
N  3  2  2  4 
2STT.  0.835  1.856  *2.430* 
2-1STT LOW  0.127  -0.990  -1.563 
2 -1STT HIGH  *1.797*  *2.722*  *3.297* 
T.  5.79  7.88  11.23  7.71
 
( ±SD)  (0.61)  (1.23)  (12.40)  (4.25)
 
N  3  2 2 4 
2STT  0.758  0.053  0.564 
2-1STT LOW  -0.149  0.530  0.811 
2-1STT HIGH  1.368  0.425  -0.317 
Table 1.1: Means and Statistics- Ethylcellulose Coatings 
a) number of subjects in average.
 
b) calculated two-sided t statistic.
 
c) calculated one-sided t statistic (low and high).
 
d) *Bold Type* indicates statistically significant difference.
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Deconvolution of preliminary biostudy data provided in vivo input functions 
for all four formulations (figure 1.07). Both 4A and 6A release drug within the 
first half hour after ingestion and exhibit approximately zero-order release 
character after 10 hours post-dosing. Formulation 8A releases drug in a zero-order 
fashion during its entire transit of the GI tract. Of the three test formulations, 4A 
comes closest to exhibiting a release pattern similar to that of the reference. 
Oruvail is formulated to resist drug release in gastric fluid(7), and figure 1.07 
shows nearly zero ketoprofen absorption from Oruvail during the first 2 hours 
post-dosing. Thus, it was deemed necessary to enteric-coat the new formulations 
to delay the onset of drug release if identical absorption curves are to be produced. 
Enteric Over Ethylcellulose Coatings 
In the second iteration of product formulation, enteric-coated beads were 
made by applying a 5% (5E/4A) and 10% (10E/4A) enteric coat over ketoprofen 
beads freshly coated with 4% ethylcellulose. Dissolution of the formulations 
(figure 1.08) shows that there may be a thinning of the ethylcellulose layer 
following removal of the enteric coat after intestinal fluid changeover. This is 
evidenced by the increased rate of drug release versus that of the non-enteric­
coated 4A following changeover from gastric to intestinal dissolution media. If 
drug had localized in the hydrated enteric coat prior to changeover, a burst of drug 
release would be expected into the intestinal media followed by a drug release 140 
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Figure 1.08: Dissolution of enteric over ethylcellulose coated ketoprofen beads 26 
pattern that would essentially parallel that of 4A. Both 5E/4A and 10E/4A have 
adequate enteric protection, but both formulations release drug faster following 
transition to intestinal fluid than virgin 4A beads. Biostudy data were gathered for 
both Test formulations and compared with the reference (figures 1.09 and 1.10). 
Statistical analysis of average dU/dt data (table 1.2) reveals bioequivalence of 
enteric-coated 4A based on a 2STT. Both formulations have AUC's that are 2­
1SIT bioequivalent to the reference, but both fail a 2-1STT of bioequivalence for 
C.,x, and are therefore not bioequivalent based on a 2-1STT. However, the 
closeness of the data between test and reference would lead to a conclusion of 
bioequivalence if the number of subjects in the study of these formulations had 
been higher. 
Input functions generated by deconvolution of biostudy data reveal that 
enteric-coated 4A has similar release characteristics to that of the Reference (figure 
1.11). Although averaged data for 10E/4A showed drug was absorbed within the 
first half hour of ingestion, it is the result of one subject experiencing rapid drug 
release, probably through early gastric emptying shortly after dosing. Remaining 
subjects had a C. at about 5 hours. The input function for 10E/4A closely 
parallels that of the reference otherwise. Similar results are observed for 5E/4A, 
but all subjects exhibited the expected delay in release due to enteric coating. This 
latter formulation was chosen to carry over into a fasted-state biostudy with a 
larger number of subjects; results of which are detailed in chapter 3. Oruvail Mean (+/-SD)
 
5E/4A Mean (+ / -SD)
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Figure 1.09: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking ketoprofen beads coated with 
4%o ethylcellulose and overcoated with a 5% enteric coat Oruvail Mean (+/-SD) 
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Figure 1.10: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking ketoprofen beads coated with 
4% ethylcellulose and overcoated with a 10% enteric coat 29 
OE/4A  5E/4A  10E/4A  Oruvail 
AUC  119.71  123.51  125.40  131.61
 
( ±SD)  (16.41)  (13.64)  (13.61)  (15.15)
 
NA  3  4  3  4 
2STT'  0.995  0.795  0.559 
2-1S1Tc LOW  1.205  *1.788*d  *1.809* 
2-1STT HIGH  *3.194*  *3.377*  *2.927* 
Cm,  9.76  11.42  12.37  11.81
 
( ±SD)  (2.51)  ( 2.43)  ( 1.73)  ( 3.62)
 
N  3  4  3  4 
2STT  0.835  0.179  0.244 
2-1STT LOW  0.127  0.905  1.271 
2-1STT HIGH  *1.797*  1.262  0.784 
T.  5.79  6.44  5.14  7.71
 
( ±SD)  (0.61)  (1.87)  (0.55)  (4.26)
 
N  3  4  3  4 
2STT  0.758  0.546  1.014 
2-1S1T LOW  -0.149  0.117  -0.406 
2-1STT HIGH  1.368  1.209  *1.623* 
Table 1.2: Means and Statistics: Enteric over Etbylcellulose Coatings 
a) number of subjects in average. 
b) calculated two-sided t statistic. 
c) calculated one-sided t statistic (low and high). 
d) *Bold Type* indicates statistically significant difference. 140 
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Figure 1.11: Deconvolved GI absorbance of ketoprofen beads layered with enteric over ethylcellulose coatings 31 
Ethylcellulose Over Enteric Coatings 
The third iteration of product formulation was carried out to test a 
hypothesis of effective internal enteric protection. Based on research conducted 
previously at Oregon State University, the effect of applying an enteric coat before 
application of controlled release polymers was studied. Research by Manse 11(10) 
demonstrated that application of an ethylcellulose layer over an inner enteric layer 
yields enteric protection while allowing control of release rate characteristics 
similar to that of beads coated with ethylcellulose alone. 
Enteric-coated beads were made by applying a 2% (2E) or 4% (4E) enteric 
coat over nude ketoprofen beads. Ethylcellulose was then applied to give 2A/2E, 
3A/2E, 4A/4E and 5A/4E. Dissolution (figure 1.12) shows that a 2% internal 
enteric coat is ineffective at preventing gastric drug release. An inner 4% enteric 
layer does not appear to greatly affect membrane-controlled diffusional drug 
release in vitro as evidenced by the similar drug release patterns of 4A/4E to 4A 
and 5E/4A to 5A. An internal 4% enteric coat was effective in providing adequate 
enteric protection, and 5A/4E is a good approximation of the reference based on in 
vitro results. However, biostudy data which were gathered for 5A/4E and 
compared with the reference (figure 1.13) suggests the hydrated enteric layer may 
remain trapped inside the ethylcellulose coat, thereby slowing drug release, which 
is consistent with the report of Mansell. Statistical analysis of average dU/dt data 
for 5A/4E (table 1.3) reveals non-equivalence to the reference based on both a 
2S1T and a 2-1STT, in spite of the similarities in in vitro dissolution patterns. '-cal 200 
E 
e 
I, 
11111111110° 
....10MPII 1IN MI II 
. .,---­
-sisiorrwwit1 
7.3  150 
a) 
0 
(/) 
Q 
4a.) 
100 
50 
e-- 2A/2E 
0 3A/2A 
A-- 4A/4E 
it 5A/4E 
Oruvial 
O 
4 
I 
5 
1  1  I 
10 
1  1  ,  1  I 
15 
1  1  I 
20 
i 
25 
Time (in hours) 
Figure 1.12: Dissolution of ethylcellulose over enteric coated ketoprofen beads Oruvail Mean (+/-SD) 
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Figure 1.13: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking ketoprofen beads coated with a 
4% enteric coat and overcoated with 5% ethylcellulose 34 
5A/4E  Oruvail 
AUC  101.09  131.61 
(±SD)  (12.17)  (15.15) 
N*  3  4 
2STT'  *2.8470 
2-1S11 LOW  -0.392 
2-1STT HIGH  *5.303* 
C..  7.54  11.81 
(±SD)  (1.68)  ( 3.62) 
N  3  4 
2STT  1.864 
2-1STT LOW  -0.833 
2-1STT HIGH  *2.896* 
Tn.  5.83  7.71 
(±SD)  (0.58)  (4.26) 
N  3  4 
2STT  0.741 
2-1STT LOW  -0.133 
2-1STT HIGH  1.349 
Table 1.3: Means and Statistics; Ethylcellulose over Enteric Coatings 
a) number of subjects in average.
 
b) calculated two-sided t statistic.
 
c) calculated one-sided t statistic (low and high).
 
d) *Bold Type* indicates statistically significant difference.
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Input functions (figure 1.14) generated by deconvolution of biostudy data 
reveal that average 5A/4E released small amounts of drug within the first half hour 
of ingestion and exhibits slow zero-order release beginning 6 hours post-dose. 
Increasing the amount of internal enteric-coat application might provide adequate in 
vivo enteric protection, but hydration of the enteric layer might burst the 
ethylcellulose overcoat resulting in dose-dumping within the small intestine. A 4% 
internal enteric coat provides some delay in in vivo drug release, but was deemed 
inadequate to provide complete enteric protection for ketoprofen bead formulation. 
Formulation of ketoprofen beads having an internal enteric coat overcoated with 
ethylcellulose was abandoned because of the risk of ethylcellulose overcoat failure 
giving rise to dose-dumping if the enteric coat was increased while decreasing the 
amount of ethylcellulose coating. ***** 
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CONCLUSIONS 
Urinary analysis of drug excretion for compounds that are extensively 
eliminated through the kidneys is a valuable, non-invasive, analytical tool. The 
effect of formulation modifications on in vivo absorption and excretion of drug 
from sustained release dosage forms can be easily and rapidly obtained. 
Under the assumptions that:  1. Each subject exhibits an invariant 
elimination rate constant for a model drug and; 2. Urinary clearance of the drug is 
dependant on input functions that in turn are dependent on release rates from test 
formulations, then the pharmacokinetics of a test formulation can be estimated by 
deconvolution of elimination rate data. Deconvolution of urinary excretion rate 
data provides a rapid, non-invasive method of assessing the effects of modifications 
in developmental drug formulations. Visual inspection of deconvolved input 
functions of test formulations versus that of a reference rapidly reveals the effects 
of modifications in controlled release formulations. 38 
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CHAPTER 2
 
PREDICTIVE EQUATION FOR POLYMER FILM-COAT
 
THICKNESS ON SPHERICAL PARTICLES
 
by Kris E. Holt 40 
ABSTRACT
 
A predictive equation for polymer film-coat thickness is derived, validated, and 
applied to estimates of spray-coater efficiency and calculations for amount of 
coating material to be applied for bioequivalent drug release compared to a 
previous bead batch. The film thickness equation is developed from considerations 
of concentric spherical shells and is proposed to replace a thickness equation 
developed by Madan, et al, based on surface area considerations. Film thickness 
(0) is given by: 
3 
100 + (% coat) 0 = R (  1)
100 
Validation by SEM of an ethylcellulose film on drug-layered nonpareils shows 
calculated 0 to be within 5% of observed thickness. Estimation of relative spray­
coater efficiencies between laboratory and industrial equipment was found to be 
surprisingly close; laboratory was 96% that of industrial equipment. An 
application is presented for calculation of amount of coating material to be applied 
to a bead batch to yield an identically thick polymer layer which is pre-requisite 
for bioequivalent drug release from bead batches with differing diameters. 
KEY WORDS: controlled release beads; film coat thickness; drug release 
prediction; bioequivalence prediction; relative coating efficiency. 41 
INTRODUCTION 
Production of extended or controlled drug release beads for oral drug 
delivery classically involves use of a polymeric film coat to slow drug dissolution 
rate. Amounts of coating materials applied are usually reported as a percentage of 
uncoated bead weight. However, control of drug release from coated beads is 
better correlated to film thickness than to weight percentage of applied film. 
Madan(1) developed an equation for theoretical film coat thickness derived from 
surface area calculations for deposition of a thin coat applied to the surface area of 
a bead batch. 
Film thickness developed by spray application of polymers to beads is a 
function of surface area which is dependent on bead diameter in the batch coated. 
As bead size increases, the number of beads per unit weight decreases 
logarithmically and total surface area decreases linearly.  Variations in finished 
bead diameter between production batches can markedly alter drug release 
characteristics because of film coat thickness variations developed by coating to a 
fixed weight gain. This effect is more important in initial formulation research 
where bead size may vary with formulation changes, and less important in multiple 
batches of commercial product where production and formulation parameters are 
held constant. 
A predictive equation was desired to relate bead diameter and applied 
polymer coating amount to resulting film coat thickness. An equation was 
developed based on bead volume for predicting the thickness of any film deposited 42 
on spherical particles. Scanning Electron Micrographs of coated bead cross-
sections were used to measure actual film thicknesses for comparison with 
predicted film thickness. Results of this research include calculation of relative 
efficiencies between laboratory and industrial spray coating equipment and 
modification of coating amount to achieve bioequivalence among multiple bead 
batches. 
MATERIALS AND METHODS 
Equation Derivation 
Let: 
0 = polymer film coat thickness in Am 
R = uncoated bead radius in Am 
(% coat) = grams of polymeric coating solids applied per 100g beads 
p  = density of uncoated bead solids (g/cm3 = g/[1012 Am3}) 
p  = density of polymeric film coat solids (g/cm3 = g/[1012 ti.m3}) 
4 q Volume of an uncoated bead =  V  = --IrR­
3
 
Volume of a coated bead = Vc =	 4ir(R + 6)3

3
 
1. Weight gain per bead based on volume and density of applied polymeric film 
coat solids is given by the product of coating density and the increase in bead 
volume due to coating material applied: 43 
pcaa(Vc  Vu) = pcoatlirRR  + e)3  Eqn 1 
2. Number of beads per gram based on radius and density of uncoated bead solids 
is given by the product of bead specific volume (reciprocal of density) and the 
reciprocal of uncoated bead volume: 
Specific Volume  1  1  1
*  Eqn 2 
VU  Plkad VU  pBead4itR3 
3 
3. Weight gain per bead based on distribution of applied polymeric film coat 
solids is given by the product of the amount of coating solids applied per 100g 
beads and the reciprocal of the number of beads per gram: 
(% coat)  1  (% coat)  4  3 
p Bead  7rR  Eqn 3 
100  (Equation 2)  100  3 
Weight gain per bead is now described by two equations based on volume change 
due to coating application (1) and weight distribution of coating applied (3). 
Setting equations 1 and 3 equal to each other yields: 
+  0)3  R3i  (%  at)  l  Eqn 4 P 3 
c°at 3 
(R + 6)3  (% coat)  Eqn 5 PBead pct 
(R 
R3  100 
(R + 0)3  100pcoat  (% coat)pBead 
Eqn 6 
100p R3 
3  100pc.aea + (% coat)pBead (R + 0)  Eqn 7 
100 p Coat 44 
3  100pcoat +  (% coat) psea 
R  Eqn 8 0 =R 
coat 
Madan Equation 
Madan developed an equation based on particle surface area, radius, and 
weight of coating material. He defined the following: 
0 = polymer film coat thickness in Am 
d = uncoated bead diameter in Am 
Ww = grams of polymeric coating applied 
W = grams of coated beads 
p = density of polymeric film coat solids 
p = density of uncoated bead solids 
Coating thickness is then given by the equation: 
p d  Eqn 9 e  )(  )( )
W  Ww  pw 6 
To translate the Madan equation into units used in the thickness equation (Eqn  8), 
note first that (W Ww) = weight of uncoated beads. By setting the weight of 
uncoated beads to 100g,  = (% coat). Also: diameter = 2(radius); p, = pc,; 
and p = per. Therefore, the Madan equation can be translated to: 
% coat)( P  )(R)  Eqn 10 e 
100  p bead  3 45 
Comparison of Equation Basis 
Because the Madan equation was derived from surface area, calculated 
thickness is directly dependent on (% coat) applied; incremental changes in (% 
coat) cause linear changes in film thickness. When employing the Madan equation, 
surface area of a particle batch is fixed once the average diameter has been 
stipulated. Thus, thickness of a developing polymer film-coat increases linearly 
with amount applied over an invariant surface area. However, concentricly applied 
spherical shells of equal volume have logarithmically decreasing thickness because 
the bead surface area increases logarithmically with each shell applied. Equation 8 
for film coating thickness was derived from deductive considerations of concentric 
spherical shell volumes and material densities, which results in the more accurate 
logarithmic relationships. 
Density Adjustments 
Density adjustments can often be ignored in thickness calculations because 
of near equivalency and their location inside a cube root in equation 8.  Therefore, 
under an assumption that bead and coating densities are equal, thickness of 
polymer films applied to spherical particles is calculated by: 
100 + (% coat) 0 = R  R  Eqn 11 
100 
Density adjustments in the Madan equation (Eqn 10) should not be ignored 
because of their direct impact on calculated film thickness. Consider three 
examples of bead and coating density pairs:  equal density; bead density twice that 46 
of coating density; and coating density slightly higher than that of bead density (as 
is often the case with plasticized ethylcellulose).  Calculated results of coating 
1.5mm beads with 10% ethylcellulose are shown in 'Bible 2.1. 
Coat  Bead  Film (0)'  Madan(' 
Density'  Density'  Thicknes  Thickness` 
s` 
1.00  1.00  24.21  25.00 
1.00  2.00  46.99  12.50 
1.29  1.19  22.39  27.10 
Table 2.1: Comparison of Film Thickness Calculated by Two Methods for 
films deposited on 1.5mm beads at a 10% w/w gain (10% coat). 
a) grams per cubic centimeter 
b) Equation 8 Note: Equation 11 when coat density equals bead density 
c) in microns 
d) Equation 10 
When bead and coating densities are equal (or are assumed to be equal in the 
absence of density information), results from equations 8 and 11 are identical. 
Under conditions of equal density, the Madan equation yields a estimate of film 
thickness that is only 3% higher than that calculated by the present equation (Eqn 
8).  In fact, the Madan equation will always yield a larger estimate of film 
thickness, regardless of bead diameter or (% coat), if bead and coat densities are 
equal. The second case involves coating a dense bead such as ethylcellulose 
applied to a barium sulfate sphere for X-ray imaging. If bead density increases, 0 47 
should increase because the number of beads per gram decreases and polymer 
application to a fixed weight gain is distributed over fewer beads. Because of the 
linear nature of the Madan equation and location of bead density in the 
denominator, calculated 0 decreases by 50% in comparison to a prediction made 
under equal density conditions. Equation 8 predicts a 94% gain in film thickness 
compared to the prediction made by equation 11. Clearly, if densities of the bead 
and coating materials differ greatly then density adjustments should be made in 
calculations of expected film thickness. However, case three involves application 
of a slightly denser coating over a bead. Expected 0 should decrease because 
weight gain due to coating should be distributed in a thinner, denser shell. This 
result is predicted by equation 8, but employment of the Madan equation gives an 
estimate that represents an 8.4% gain in film thickness in comparison to a 
prediction made under equal density conditions. Note that equation 8 over­
estimates resulting film thickness by only 8% while the Maddan equation, with and 
without density adjustments, over-estimates by 21% and 12%, respectively. 
Computer spreadsheet programs will easily generate large tables of values 
of 0 for various particle diameters and amounts of (% coat) applied. Such was 
used to generate a table of 0 from Equation 11 for beads 0.3-4mm at coating levels 
up to 15%. A plot of calculated 0 is given in figure 2.01 showing estimated film 
thickness resulting from application of (% coat) on fixed diameter beads. 100 
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Figure 2.01: Calculated film-coat thickness for applications of 0-15% coating  material on beads 0.3-4 0mm in diameter 49 
RESULTS AND DISCUSSION 
Literature Review 
Several authors (listed below) have recently cited the work of Madan for 
calculation of coating thickness on microcapsules. Three distinct methods of 
coating particles are represented by the following papers. 
Interfacial Polymerization. Ohtsubo, et al(3), calculated wall thickness 
using the sum of all potential solids that could be incorporated into the coating as 
the weight of wall material.  Greatest 0 calculated was 0.287gm and was 
unconfirmed by any microscopic method. 
Coacervation. Moldenhauer and Nairn(2) determined the weight of wall 
material for thickness calculation after solvent extraction of capsule contents. 
Greatest 0 calculated was 12.94Am for 40-50Am beads with a 29% coat and was 
unconfirmed by any microscopic method. Tirkkonen and Paronen(4) created 
microcapsules using a coacervation method while incorporating solid NaC1 into the 
coat as it formed. Weight of wall material for thickness calculation was the sum 
of all potential solids that could be incorporated into the coating. Greatest 0 
calculated was 18.9gm for coated ascorbic acid crystals incorporating NaCl into 
the film-coat. Although SEM micrographs are given of surface morphology, cross-
sectional film thickness measurements of fractured microcapsules were not 
reported. Pug lisi, et al(5), appears to use all potential coating solids as the wall 
material weight for thickness calculation. Diameter was mean of weighted sieve 
fractions ranging from 200tim to greater than 1000Am. Greatest 9 calculated was 50 
15.57Am. Although capsules were observed by SEM, cross-sectional film 
thickness measurements of fractured microcapsules were not reported. 
Spray Coating. Vyas and Dixit(6) spray-coated dry, granulated drug 
formulation particles. Maximum 0 presented is 20.40Am, but no indication is 
made as to whether this was a calculated or observed measurement; no parameters 
are given for wall thickness calculations. The Madan paper is referenced for 
calculation of a "mean volume surface diameter", but the equation is not in the 
Madan paper and tabled values do not contain this statistic. Manse 11(7) 
encapsulated drug-layered nonpareil beads. Weight of wall material for thickness 
calculation was theoretical weight gain of coating solids applied. Calculated O's 
range from 16% less to 212% greater than actual coating thickness measured by 
SEM. Hossain and Ayres(8) also encapsulated drug-layered non-pareil beads. 
Weight of wall material for thickness calculation was theoretical weight gain of 
coating solids applied. Calculated O's range from 295% to 76% greater than actual 
coating thickness measured by SEM as applied coating increases from 1% to 6%. 
Equation Confirmation 
Spherical, drug-layered non-pareil beads 1.5mm diameter were coated with 
1-8% film coat solids using a laboratory bottom-spray coating apparatus with a 
wurster insert. Beads were fractured under liquid nitrogen for examination by 
Scanning Electron Microscopy. Each micrograph was measured in multiple areas 
to determine average film thickness. Measured film-coat thickness over the coating 
range tested is shown in figure 2.02. .,.''  Mat t' 
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Figure 2.02: Measured film thickness from SEM micrographs compared to predicted 0. Beads produced and coated 
in laboratory equipment 
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Note that measured and calculated 0 agree closely over a coating range of 1-5%. 
The low thickness measured for 8% coating is probably due to an abnormally thin 
coat on the single bead measured for this coating level.  Calculated 0 generated by 
the Madan equation (without density adjustment) is shown for comparison in figure 
2.02, and is quite close to the Eqn 8 predictions and measured results in this case, 
which suggests that bead and coating densities are about equal. For further 
confirmation, similar drug-layered nonpareil beads (1.27mm diameter) produced on 
an industrial scale and coated with industrial equipment to levels of 3-5% were 
fractured and measured under SEM. Results are shown in figure 2.03. Higher 
degree of variability in measured film thickness is most likely due to variations in 
measured bead diameter. Beads were chosen from a sieve fraction of a non­
homogeneous batch. The level of magnification used to visualize film thickness 
precludes diameter measurements. Had these measurements been taken, measured 
film thickness could have been scaled to a single bead diameter, and variability 
would have been significantly reduced. Predictions of film thickness are based on 
the harmonic average of sieve fraction diameters. Predicted 0's were 102-105% of 
regressed film thickness measurements over the range of coating applications 
tested; Madan equation predictions are 103-106% of regressed film thickness 
measurements. In addition, data presented by Hossain and Ayres8 were sufficiently 
detailed to allow application of the thickness equation (11). New estimates of 0 
were found to range from 241% to 42% greater than actual coating thickness 
measured by SEM as applied coating increases from 1% to 6%; 18% to 44% less 
thick than predicted by the Madan equation. 12 
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Figure 2.03: Measured film thickness from SEM micrographs compared to predicted 0. Beads produced and coated 
in industrial equipment 54 
It was suggested that much of the coating material was lost through the top or to 
the sides of the coating chamber. 
Equation Application 
Relative Spray-Coater Efficiency. Scale-up of drug-layered nonpareil bead 
production using industrial equipment with a 32 inch wurster column produced 
249kg of heterogeneous beads 0.4-3mm in diameter, the bulk of which were in the 
0.8-1.7mm range. A 50kg portion of these were coated industrially to a 5% 
weight gain with ethylcellulose. Thickness measurements were made on a coated-
bead sieve fraction 1.27mm in diameter that were fractured with liquid nitrogen 
and viewed under SEM. Application of the same polymeric film coat was also 
conducted on a small but homogeneous batch of 1.5mm beads produced in our 
pharmaceutics laboratory. Beads produced by laboratory coat-application were 
similarly fractured with liquid nitrogen and viewed under SEM. 
Theoretically, a polymer coating is evenly distributed over the surface area 
of the bead batch. Identical polymer coats of equal thickness should yield identical 
drug dissolution patterns. Problems arise when coating bead batches of 
heterogeneous or un-equal diameters. To estimate relative efficiencies of the two 
coating systems, Table 2.2 was constructed containing information about the sieved 
weight fractions of the heterogeneous bead batch. 55 
Sieve  Average  Beads per  Surface  Percent Total  Apparent 
Fraction'  Diameter'  Gram'  Area'  Surface Area'  % coae 
20.64  1483  586  40.46  14.00  3.39 
11.85  1267  939  47.36  9.41  3.97 
67.52  887  2737  67.64  76.59  5.67 
Table 2: Characteristics of Industrially Produced Beads. 
a) Fractions of bead batch after stacked sequential sieving:  10-12, 12-14, 
and 14-20 mesh. 
b) Harmonic mean of mesh sizes producing fraction. 
c) Equation 2; assuming density of bead solids is 1.00g/cm3. 
d) 41-R2 calculated at average diameter and beads per gram. 
e) Relative contribution of each fraction towards total bead surface area in 
batch. 
f) Calculated film thickness resulting from application of 5% weight gain to 
non-homogeneous bead batch with weight fractions and bead 
diameters listed. 
Percent of Total Weight in Sieve Fraction is an indication of size distribution 
within the batch. Average Diameter of each Sieve Fraction is a harmonic mean, 
rather than average, of diameters passed by sieves in series (n/E[l/diameter]) 
because of greater surface area of small beads in a fraction. Number of Beads per 
Gram in the sieve fraction is calculated by equation 2 at the average diameter 
determined above assuming that density of bead solids is 1g/crre. Surface Area per 
gram is calculated for the number of beads per gram given above. Surface area of 
a sphere is the first derivative of sphere volume. Percent Total Surface Area for 
Weight Fraction is the fraction of total surface area in the bead batch contributed 
by each sieve fraction.  Total surface area is the sum of (Surface Area per 
Gram)*(Percent of Total Weight in Sieve Fraction) for the three sieve fractions. 56 
Relative efficiencies of the two spray-coating systems in applying a 5% polymer 
film can be calculated from: 
(Apparent % Laboratory Coat)  Eqn 12 Relative Efficiency 
(Apparent % Industrial Coat) 
(% Coat)  (% Coat).(Fractional Surface Area)  Eqn 13
Apparent  Labeled  (Fractional Weight) 
where Labeled % Coat is the measured weight gain of a coated bead batch after 
application of film-coat solids. 
Calculated Apparent % Coats applied to industrially-produced bead size 
fractions are 3.39%, 3.97%, and 5.67%, respectively, for 1483, 1267, and 887Am 
beads when the labeled % coat is 5%. Relative efficiency of the industrial coating 
system in applying 5% ethylcellulose to 1267Am bead fraction is 126% compared 
to Oregon State University bench top coating equipment. (Apparent % Coat) 
applied to 1.5mm beads in the laboratories of Oregon State University is (Labeled 
% Coat) because of homogeneous bead size. However, relative efficiencies of the 
two coating systems has little bearing on the drug release characteristics of the 
formulations produced. Relative efficiency is an expectation of the relative film 
thicknesses developed by the two coating systems in coating one size fraction of a 
non-homogeneous bead batch versus coating a homogeneous bead batch. Drug 
release characteristics of a coated non-homogeneous bead formulation is more 
closely predicted by apparent % coat and the size of the weight fraction to which it 
was applied. In vitro release studies show that the combination of weight fractions 
and coating thickness on those weight fractions of a non-homogeneous, industrially 
produced and coated, bead batch had an average drug release rate that was similar 57 
to that for mixture of coating levels on homogeneous beads. Figure 2.04 shows 
that initial drug release rate from coated non-homogeneous beads is more closely 
approximated by that of homogeneous beads coated at the 2% level, and slower 
throughout the majority of the time of drug release than homogeneous beads coated 
with 6% ethylcellulose.  Overall, the dissolution curve for non-homogeneous beads 
coated with 5% ethylcellulose appears to be a combination of release rates, through 
dose additivity, of a variety of coating levels and weight fractions. 
True efficiency of the industrial coating system compared to that employed 
in the laboratory can be calculated from the amount of coating material required to 
coat an identical, homogeneous bead batch to an identical film coat thickness. 
Using equation 11 and the SEM-measured film thicknesses shown in figures 2.02 
and 2.03, a polymer film coat of 4.82% applied industrially is predicted to yield an 
identical coat thickness on an identical, homogeneous bead batch coated at 5% by 
laboratory equipment. Therefore, efficiency of the industrial coating system is 
104% relative to the laboratory spray-coater. This is a surprisingly close 
agreement in coating efficiencies. 
Modification of Coating Amount. Suppose that a homogeneous drug-
layered bead batch of 1.5mm diameter yields a desired in vitro release pattern 
when coated to a 5% weight gain with a controlled release polymer film. Figure 
2.01 shows the expected coating thickness is 12.5Am. Further assume that during 
the next production of beads, drug layering is halted at a stage yielding 
homogeneous beads 1.3mm in diameter. Rather than multiple coating trials with a 
range of percent-weight gains to find the equivalent release pattern, employment of 120
 
18 100 
c.) 
as 
0 0 ' 
75  80 
P4 
to 
60 
A' 
4 40 
a)
U 
;-( 
Pk  0  20 
e Homogeneous Beads, 2% ethylcellulose coat 
10-- Homogeneous Beads, 3% ethylcellulose coat 
-13- Homogeneous Beads, 4% ethylcellulose coat 
11-- Homogeneous Beads, 5% ethylcellulose coat 
--er Homogeneous Beads, 6% ethylcellulose coat 
Non-Homogeneous Beads, 5% coat 
i  I  I  I  I  I  I 
5  10  15  20  25 
Time (in hours) 
Figure 2.04: Dissolution of ketoprofen from ethylcellulose-coated beads. Comparison of homogeneous beads 
versus non-homogeneous beads 59 
equation 11, displayed graphically as figure 2.01, gives a prediction of equivalent 
12.5Am film thickness when 1.3mm drug beads are coated to a 5.78% weight gain 
(equivalent to when 1.5mm diameter beads are coated to a 5% weight gain). 
CONCLUSIONS 
Polymer film coat thickness is a function of bead diameter and amount of 
film solids applied. The Film Thickness (0) equation (Eqn. 9) is accurate in 
predicting ethylcellulose films on spherical beads applied both industrially and in a 
laboratory setting. One application of the Film Thickness equation is a calculation 
of relative efficiencies between spray coating apparati. Another application would 
be adjustments in polymer amount applied to bead batches of differing diameters to 
achieve an identical film thickness. Since dissolution of drug through a controlled 
release polymer coating is related to film thickness, drug-layered beads of differing 
diameters having identically thick film coats should have nearly identical in vitro 
and in vivo release patterns. 60 
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CHAPTER 3
 
FORMULATION OF KETOPROFEN BEADS BIOEQUIVALENT
 
TO ORUVAIL.
 
by Kris E. Holt and James W. Ayres 62 
ABSTRACT
 
Purpose: Manufacture of a ketoprofen capsule formulation bioequivalent to 
Oruvail. Technology transfer of a laboratory process through scale-up to an 
industrially-produced experimental bead batch. 
Method: Beads manufactured by spray-layering drug and binders in aqueous 
suspension onto nonpareil seeds. Beads coated with ethylcellulose and 
methacrylate to provide dissolution barriers and enteric protection of varying 
strengths. Biostudies with human subjects tracked urinary ketoprofen excretion 
rates. Deconvolution of biostudy data used to determine in vivo dissolution rates 
(input functions) as a method of comparing effects of formulation modification and 
to suggest further modifications in formulation toward convergence with 
bioequivalence.  Statistical testing of urinary excretion rate parameters by two 1­
sided T tests was final proof of achievement of bioequivalence with reference 
formulation. 
Results: Urinary excretion rates of ketoprofen from fasted subjects parallels 
published plasma drug concentrations. Deconvolved input functions allowed rapid 
selection of candidate formulations for bioequivalence testing. Human biostudies 
revealed that ketoprofen beads coated with 5% ethylcellulose and overcoated with 
an effective enteric bather of methacrylate were bioequivalent to Oruvail when 
urinary excretion rates were monitored. 
Conclusion: 6E/5A/IND is bioequivalent to Oruvail. Deconvolution of biostudy 
data can be used for formulation modification towards bioequivalence. Urinary 
excretion rate of ketoprofen is an accurate reflection of plasma drug concentration. 63 
INTRODUCTION 
This study covers the formulation modifications and biostudy testing of a 
ketoprofen bead formulation towards bioequivalence with Oruvail. Deconvolution 
of non-invasive drug excretion rate data used to suggest modifications to drug 
formulation in order to obtain bioequivalence with commercial standard. Previous 
data(1) covered use of deconvolution to suggest formulation modifications. 
Formulations were administered in a fed state following a standardized breakfast. 
However, CDER (Center for Drug Evaluation and Research) regulations(2) 
stipulate extensive testing under fasting conditions for establishment of 
bioequivalence between test and reference formulations. This report establishes 
bioequivalence in a new oral controlled-release formulation of ketoprofen under 
fasting conditions. 
Standard in vivo sampling requires timed blood draws for analysis of 
circulating drug concentrations. Blood sampling of human subjects is undesirable, 
at least in the initial stages of formulation development, because of discomfort, 
expectation of recompense, and the possible communication of blood-borne 
diseases. Analysis of drugs in urine is non-invasive in that no penetrative 
procedures are used for sampling. 
Since drug excretion rates in urine have been shown to parallel serum drug 
concentrations, analysis of drug excretion gives evidence of in vivo performance of 
test formulations. Thus, analysis of urinary excretion data are useful in developing 
new product formulations. This is especially true for older, established drugs 
where pharmacokinetic data and drug concentrations in blood have already been 64 
published and are available for comparison to urinary excretion rate data. This 
paper details formulation modification based on in vivo input functions for test 
formulations determined by deconvolution of excretion rate data of ketoprofen 
administered under fasting conditions. In vivo input functions and their 
correlations to in vitro dissolution were used to modify a drug formulation towards 
a desired release pattern. The technique employed is applicable to any model drug 
that is extensively excreted through renal filtration as either parent drug or 
metabolite. 
MATERIALS AND METHODS 
Materials 
Ketoprofen was chosen as the model drug for this report. The commercial 
reference used was Oruvail, produced by 'Wyeth-Ayerst. Ketoprofen, 
hydroxypropylcellulose (Klucel EF), polyvinylpyrrolidone K-30 (PVP), dibutyl 
sebacate (DBS), triethyl citrate (TEC), talc, and polysorbate 80 were all either 
USP/NF or reagent grade. Ethylcellulose-coat working solutions for spray 
application contained 100g Aquacoat (FMC), 100g water, and 6.7g each of DBS 
and TEC. Enteric-coat (methacrylate) working solutions for spray application 
contained 100g Eudragit L30D-55 (Rh Om Pharma), 3g DBS, 7g talc, 0.2g 
polysorbate 80, and 89.8g water. 65 
Product formulation 
Drug formulations were manufactured by spray-layering to produce beads 
for inclusion in capsules. Industrial scale-up of bead production began with 15kg 
of 50 mesh nonpareils in an 18 inch Wurster. Layering suspension containing 
45kg ketoprofen, 1.125kg Klucel, and 2.25kg PVP was applied to yield 63.375kg 
of 71% ketoprofen beads. The batch was separated into two 30kg sub-batches and 
each was layered with a suspension of 30kg ketoprofen, 0.75kg Klucel, and 1.5kg 
PVP for a combined yield of 124.5kg of 82.4% ketoprofen beads. The final layer 
was 120kg ketoprofen, 3kg Klucel, and 6kg PVP applied to 120kg of the previous 
beads in a 36 inch Wurster. The completed formulation was 249kg of drug-
layered beads containing 87.9% ketoprofen with the balance being sugar core and 
binder. This batch of beads is extensively evaluated in this report and is identified 
as "IND" product. Size distribution of the formulation is given in Table 3.1. 
Dissolution 
USP Method 2 in simulated gastric fluid (pH 1.4; no enzymes) at 50 rpm. 
After 2 hours gastric pretreatment, formulations were filtered from media and 
added into simulated intestinal fluid (SIF, pH 7.4; no enzymes) to continue the 
dissolution study. 
Samples were diluted 1:10 (1 ml plus 9 ml diluent) with SW and analyzed 
at 254nm against known concentrations of drug in the range of 0 to 25 µg /ml of 
ketoprofen in SIF.  Candidate formulations that gave drug dissolution similar to a 
desired drug release pattern were selected for in vivo testing. 66 
Mesh  Diam.  Frac.  Cut  Ave.  Beads  Surf.  Frac.
 
Size'  (iimr  Wt 9be  9E,d  Diam.`  per gf  Areas  Areal'
 
>6  3330  0.41  0.00 
>10  1650  13.79  0.00 
>12  1400  16.46  20.64  1483  586  40.46  14.00 
>14  1200  9.45  11.85  1267  939  47.36  9.41 
>20  830  53.85  67.52  887  2737  67.64  76.59 
>50  300  6.04  0.00 
Table 3.1: Characteristics of IND Beads after stacked sequential sieving. 
a) Taylor designation sieves 
b) Mesh opening 
c) Fractional weight remaining after discarding larger and smaller beads 
d) Harmonic mean of the current and previous mesh size 
e)  Calculated assuming density of bead solids is 1.00 
f)  Calculated at average diameter and beads per gram 
h) Relative contribution of each fraction towards total surface area 
Urinalysis 
In vivo testing of formulations used human volunteers in a cross-over 
design. Subjects fasted overnight, provided a zero-time urine sample prior to 
dosing, then ingested a formulation. Subjects collected the contents of their 
bladders in 24oz Whirl-Pak bags at scheduled sampling times of 0-12 hours post-
dose in 1 hr increments, and at 16, 24, 28, 32, and 36 hrs.  Caffeineated 
beverages were withheld for 2 hours post-dosing, but water was allowed ad lib. A 
standardized breakfast of a bagel with loz cream cheese and a 10oz pre-packaged 
fruit drink were provided following collection of the 2hr sample. 67 
Drug content assay of urine samples is detailed in previous paper as a 
modification of that presented by Upton(3). Standard curves of ketoprofen in 
blank urine ranged from 2/4/m1 to 300/4/m1 with an internal standard of 63 µg /ml 
of naproxen. Standards were treated identically to all other urine samples during 
the analysis procedure. Volume and time elapsed since drug ingestion were 
recorded for each urine sample and a portion was saved for drug concentration 
measurement. Assay procedure provides for hydrolysis of glucuronide metabolites 
so that total ketoprofen excretion could be monitored, and ether  extraction is used 
to segregate analyte and internal standard from urine chromophores. 
Mobile phase for HPLC analysis was 43% acetonitrile plus 4m1 glacial 
acetic acid per liter of solution (pH approximately 3.5). Dried sample extracts 
were dissolved in mobile phase. HPLC proceeded at lml/min flow rate through a 
5A, 100A C18 0.46 x 1.5cm guard column and 51h, 100A C18 0.46 x 25cm 
analytical column (Microsorb-MV, Rainin). Absorbance was monitored at 254nm. 
Ketoprofen elutes first at 9 minutes after injection, with naproxen internal standard 
following at 11 minutes. 
Deconvolution 
The theory and process of deconvolution is covered extensively in the 
previous paper(1). In brief, deconvolution is the mathematical process employed 
to find the in vivo drug input function that balances an observed response to drug 
input with a characteristic degradation or elimination function unique to a 
drug/subject pair. Functions used in deconvolution for this study are as follows: 68 
Response = c(t) = Function which describes the time-course of urinary 
excretion rate of drug for the oral controlled release product being 
evaluated. Response function in this study is urinary excretion rate, or 
dU/dt. 
Impulse response = c8 = Function that describes the time-course of change in 
urinary excretion rate of drug following an IV bolus dose. Impulse 
response was approximated by a mono-exponential function with a 
literature-derived elimination rate constant as the exponential factor. 
The above parameters were fit to the convolution integral: 
c(t) = (c8 *.f)(t) = fotca(t tAt)ch 
and solved for input rate using the computer program PCDCON(4). Input rate = 
f(t) = is the function which describes the time-course of in vivo absorption rate of 
drug from the GI tract. For controlled release formulations, under an assumption 
that absorption is dissolution-rate limited, input rate is also the in vivo dissolution 
rate function. Bioequivalent formulations have equivalent input rate functions. 
Integration of in vivo input rate functions obtained from deconvolution gives 
cumulative amounts of drug absorbed, which is cumulative amount of in vivo 
dissolution when absorption is dissolution-rate limited. Cumulative amount 
dissolved in vivo versus time is referred to as the input function in this report. 
Input functions can be used to develop in vitro I in vivo dissolution (i.e., in vitro 
dissolution versus in vivo absorption) correlations. Deconvolved input functions 
from different controlled release formulations can be rapidly compared by visual 69 
inspection for relative equivalence of rates and extents of in vivo dissolution. 
Convolution can then be used to predict in vivo excretion rate data from in vitro 
dissolution data without further in vivo study. 
Conventions 
Coatings were applied as a w/w increase to ketoprofen beads. Hence, 5% 
ethylcellulose indicates a 5g weight gain to 100g nude drug-layered beads. This 
formulation would be designated 5A in this report. Multiple layers are read as 
exterior to interior; 5E/5A indicates 5g enteric coat over 100g of 5A beads. 
Since urinary excretion was followed in the course of this study, C,,,L, 
corresponds to the maximum excretion rate; T x to the time of maximum excretion 
rate; and AUC to the area under the excretion rate versus time curve.  The 
subscripts R and T refer to the Reference (Oruvail) and Test formulations. All 
statistical results reported are for comparison of a new Test formulation parameter 
to that of Oruvail (reference standard). 
Statistics 
Two sets of statistics are reported: a two-sided Student t test at a =0.05 on 
the null hypothesis Ho: pr-AR = 0 and the two one-sided t test(5) at a=0.10 on the 
null hypotheses Hoi: p,r <0.8pR and H02: AT > 1.2pR. Interpretation of results is 
given as follows: 
Two-sided t test (2STT): Acceptance of the null hypothesis (Ho) indicates 
that there is not enough evidence to conclude a significant difference exists 70 
between the parameter mean of the Test formulation and the corresponding 
parameter mean of the Reference; i.e., the parameters are equivalent. Rejection of 
the null hypothesis is a strong indication of non-bioequivalence for the two 
formulations. 
Two one-sided t test (2-1STT): Acceptance of either of the two hypotheses 
indicates that there is not enough evidence to exclude the possibility that p.T is 
higher or lower than AR+20%, respectively, which are the criteria for 
bioequivalence(6). Bioequivalence can only be concluded when both null 
hypotheses are rejected. Therefore, acceptance of one or both null hypotheses is 
defined as non-bioequivalence. 
RESULTS AND DISCUSSION 
Introduction 
Biostudies of Oruvail under fasting conditions gave urinary excretion rate 
data that coincided well with scaled ketoprofen blood concentration data given in 
the Oruvail product insert (figure 3.01). Data from a second report of average 
Oruvail blood concentrations versus time(7) is given as a comparison. Urinary 
excretion rates are expected to parallel plasma drug concentrations, and results in 
figure 3.01 are good confirmation that urinary excretion rates can be used in 
preliminary bioavailability comparisons. 
Oruvail is available in three strengths: 100, 150 and 200mg. Analysis of 
fill-volumes and dissolution results (figure 3.02) indicates that all three strengths 
are appropriate amounts of the same formulation. Guidances for controlled  release 5 
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Figure 3.01: Comparison of mean ketoprofen excretion rate eata to published concentrations following ingestion of Oruvail 120
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Figure 3.02: Dissolution of Oruvail -- comparison of 100, 150,and 200mg strengths 
25 73 
dosage forms(6,8) indicate that bioequivalence need be established only for the 
highest strength capsule when dosage strength is dependent solely on amount of 
formulation present. 
In order to more fully control some influences of factors external to 
bioequivalence, subjects were asked to fast 12 hours prior and 2 hours post-dosing. 
Previously, subjects were dosed while taking a standard breakfast. Oral Oruvail 
tested under fasted conditions was found to peak faster and higher than in the fed 
state (figure 3.03). This result is in agreement with the findings of Le-Liboux(9). 
Ethylcellulose Over Enteric Coatings 
Ketoprofen beads produced at Oregon State University, coated with 4% 
methacrylate and overcoated with 5% ethylcellulose (5A/4E/ICEH), provided an in 
vivo release pattern of ketoprofen that was similar to that of Oruvail (figure 3.04). 
Anticipation of similar results from beads produced by industrial scale-up led to 
consideration of a similar coating system for the new (BIO) beads. In the BIO 
production run, resulting beads were of diameters ranging from 400 gm to a few 
very large beads of 6mm (Table 3.1). 
The largest beads appear to be made by aggregation because few are regular 
spheres. Non-uniformity of beads may increase difficulty of scale-up or transfer of 
previous formulation results in a predictive manner for in vitro / in vivo dissolution 
correlations. Larger beads develop a disproportionately thick coat within a wurster 
insert during a coating operation. Thus, the first laboratory scale coating system 20 
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Figure 3.03: Mean ketoprofen excretion rates of subjects taking Oruvail under fed and fasted conditions 20 
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Figure 3.04: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking beads coated with 
4% enteric coat and overcoated with 5% ethylcellulose 
25 76 
applied to IND beads was 3% ethylcellulose overcoated onto 4% methacrylate on 
800g unsieved beads (3A/4E/IND). 
3A/4E/IND: Deconvolution of urinary excretion rate data from two 
subjects taking 3A/4E/1ND in a preliminary biostudy showed an earlier and more 
rapid input of ketoprofen from the gut (figure 3.05). Data from two subjects do 
not, of course, have any useful statistical power and are only useful if trends in 
response vs. time curves are consistent with expected formulation modifications. 
See table 3.2 for all AUC, Cmax, Tmax, and statistical calculation values. 
Averages of excretion rate data are given in figure 3.06. Interpretation of these 
preliminary results was that 3A/4E/IND would not be bioequivalent to Oruvail in a 
larger study; thus no additional subjects were given the formulation. A coat of 4% 
methacrylate on IND beads was not sufficient to prevent early gastric dissolution, 
and consequently early onset of urinary excretion  Early gastric dissolution would 
be likely if the smaller beads in the batch had an incomplete enteric coat. 
Similarly, 3% ethylcellulose was insufficient to provide the desired level of control 
on the release of ketoprofen from 3A/4E/IND beads, leading to a rate of release 
that was too high to produce bioequivalence. 
5A/4E/IND: The 3A/4E/IND batch was overcoated with an additional 2% 
ethylcellulose to yield 5A/4E/IND. Beads were then sieved to reject beads greater 
than 1650 pm (retained on 10 mesh) and less than 830 pm (passed by 20 mesh) in 
diameter; a loss of about 20% of the batch. 5  10  15  20 
Time (in hours) 
Figure 3.05: Deconvolved GI absorbance of ketoprofen from Oruvail versus beads coated with 4% enteric coat 
and overcoated with 3% ethylcellulose 
25 78 
3A/4EJIND  5A/4E/IND  6E/5AJIND  Oruvail 
AUC  108.54  85.63  113.42  115.70 
(±SD)  (44.02)  (37.32)  (29.95)  (29.77) 
Isla  2  11  7  12 
2ST1*  0.300  *2.145*d  0.161 
2-1ST7  0.670  -0.494  *1.470* 
LOW 
2-1ST1'  1.271  *3.796*  *1.792* 
HIGH 
C  30.14  11.46  14.80  15.48 
( ±SD)  (22.36)  ( 6.43)  ( 3.62)  ( 5.98) 
N  2  11  8 13 
2STT  *2.283*  1.586  0.289 
2-1STT  *2.776*  -0.364  1.026 
LOW 
2-1STT  -1.802  *2.806*  *1.604* 
HIGH 
TE.  5.38  6.48  5.31  7.21 
( ±SD)  (3.00)  (2.42)  (1.73)  (2.11) 
N  2  11  8 13 
2SIT  1.099  0.790  *2.137* 
2-1STT  *2.766*  -0.364  1.026 
LOW 
2-1STT  -1.802  *2.806*  *1.604* 
HIGH 
'able 3.2:  Means and Statistics; Ethylcellulose over Enteric Coatings. 
a) number of subjects in average. 
b) calculated two-sided t statistic. 
c) calculated one-sided t statistic (low and high). 
d) *Bold Type* indicates statistically significant difference. 60 
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Figure 3.06: Mean ketoprofen excretion rates of subjects taking Oruvail  versus those taking beads coated with 
4% enteric coat and overcoated with 3% ethylcellulose 80 
Larger beads add a slow controlled release (CR) component to dissolution of 
5A/4E/IND because of the disproportionately thick layer of polymer deposited 
during coating; smaller beads result in an immediate release (IR) component 
because an incomplete coat is formed over the enormous surface area of the beads. 
Eleven subjects participated in the bioequivalence study of this formulation. 
Average excretion rate data are given in figure 3.07. 
AUC for the 5A/4E/IND formulation was significantly lower by the 2STT, 
and AUC, C.., and T. of the test formulation were accepted as being lower than 
80% of the reference by the 2-1STT. Therefore 5A /4E /IND is not bioequivalent 
to Oruvail. See table 3.2 for all AUC, C,,,,,,, Tmu, and statistical calculation 
values. Deconvolution of urinary excretion rates from subjects taking 5A/4E/IND 
shows adequate lag time before onset of in vivo dissolution, but the rate and extent 
of release was too low to produce bioequivalence (figure 3.08). 
The extent of decreased ketoprofen release in switching from 3% to 5% 
ethylcellulose on 4E/IND beads is surprising.  It is possible that sieving to use only 
beads in the 830-1650Am range removed incompletely coated beads. In this case, 
sieved 3A/4E/IND might give much better results. However, no further 
investigation was undertaken for ethylcellulose over methacrylate formulations are 
planned because of success following reversal of the coating sequence as described 
below. Oruvail Mean (+/-SD) 
5A/4E/IND Mean (+/-SD) 
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Figure 3.07: Mean ketoprofen excretion rates of subjects taking Oruvail versus those taking beads coated with 
4% enteric coat and overcoated with 5% ethylcellulose 5  10  15  20 
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Figure 3.08: Deconvolved GI absorbance of ketoprofen from Oruvail versus beads coated with 4% enteric coat 
and overcoated with 5% ethylcellulose 
25 83 
Methacrylate Over Ethylcellulose Coatings 
Industrial Coating Trial: Methacrylate over ethylcellulose coating systems 
have been extensively studied at Oregon State University, and have proved to be 
robust for tailoring drug dissolution from controlled release beads. Accordingly, 
36.5kg of sieved IND beads (10-30 mesh) were coated with 5% ethylcellulose 
using industrial equipment. Samples (250g) were taken at 0.25% increments in 
coating between 1% and 5% ethylcellulose applications (1.00A/1ND - 5.00AAND). 
methacrylate was overcoated onto 30kg of the resulting 5A/IND beads to a level of 
8%. Samples were again collected, but at 0.5% increments in coating amounts 
between 2% and 8% methacrylate applications (2.0E/5A/IND  8.0E/5A /IND). 
Dissolution: Dissolution data of IND beads coated with various amounts of 
ethylcellulose alone are given in figure 3.09. Results from 2 hour gastric fluid 
pretreatment show that 2% or more ethylcellulose is required to establish a 
diffusional barrier to begin controlling release of ketoprofen from IND beads. At 
4% coating of ethylcellulose, less than 10% of the labeled amount of drug is 
released in gastric pretreatment, while 80% of the dose is released in 12-15 hours. 
Dissolution data of 5A/IND beads overcoated with various weights of 
methacrylate are given in figure 3.10. Amount of methacrylate applied does not 
substantially affect rate or extent to which ketoprofen is released from 5A/IND 
beads in intestinal fluid. 250 
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Figure 3.10: Dissolution of 5MIND beads overcoated with various weights of methacrylate 86 
This is consistent with previous research at Oregon State University. Small but 
significant differences are found in the pretreatment phase: 10% drug release from 
2% methacrylate overcoated beads; 0.5% release from 3% overcoated; 0.1% 
release from 3.5% overcoated. Because of the requirement for an enteric coat to 
prevent drug release in gastric fluid followed by controlled release in intestinal 
fluid, the formulation chosen for the next bioequivalence study iteration was 
6E/5AT1ND. 
6E/5A/IND: Deconvolution of urinary excretion rates from 8 subjects 
taking 6E/5A/IND shows fairly good agreement with the input function ofOruvail 
(figure 3.11). Figure 3.12 shows the relative excretion rates of Oruvail and 
6E/5A/IND, and table 3.2 shows numerical values for pharmacokinetic parameters 
of interest. Average AUC of the test formulation is equivalent to average AUC of 
Oruvail (113 vs 115). They are not statistically significantly different by the 
2STT. C.,,, of 6E/5A/IND and Oruvail differ by less than 5% and should be 
considered essentially equal. The 2-1STT for the null hypothesis that C. of the 
test formulation is lower than 80% of the same parameter of Oruvail cannot quite 
be rejected due to the large standard deviation for Oruvail data. Failure to satisfy 
the 2-1STT means that the test is not appropriate for highly variable products like 
Oruvail. Although the FDA requires that the 2-1STT be conducted, the results 
may not be a basis for rejection of bioequivalence when there is less than 5% 
difference in C. values. 5  10  15 20 25 
Time (in hours) 
Figure 3.11: Deconvolved GI absorbance of ketoprofen from Oruvail versus beads coated with 5% ethylcellulose 
and overcoated with a 6% enteric coat ^1_4  20 
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Figure 3.12: Mean ketoprofen excretion rates of subjects taking Oruvail  versus those taking beads coated with 
5% ethylcellulose and overcoated with a 6% enteric coat 
25 89 
A 2sTr shows that Taux is statistically significantly low and is mirrored by 
acceptance of Hot in the 2-1STT for Trap (see table 3.2 for all AUC Cmax, Tmax, 
and statistical calculation values). Although T. for individuals is shorter for the 
test formulation than that of Oruvail (table 3.2), Tma, is not a critical parameter. 
Time to peak values are not required to be equivalent for bioequivalence of 
controlled release products. The time lag prior to drug release for 6E/5A/IND 
could be an hour longer, but overall rate and extent of release is quite similar to 
that of Oruvail. 
A point-by-point statistical comparison of dU/dt versus time for 6E/5A /IND 
and Oruvail using the 2STT shows the two formulations to be equivalent over all 
time intervals except 1.25-2.1 hours and 9-12 hours post-dosing. Slowing in vivo 
onset of dissolution by increasing the applied coat of ethylcellulose should shift the 
6E/5A/IND dU/dt curve to the right, which would better align the two curves for 
average excretion rates. 
Figures 3.01 and 3.12 demonstrate the high variability of data gathered in 
this biostudy on excretion of ketoprofen released from Oruvail and 6E/5A/IND. 
Variability is a critical factor in a point-by-point comparison of average excretion 
rates of 6E/5A/IND and Oruvail. A number of investigators have called for a 
relaxation of statistical testing of bioequivalence cut-off points (80% and 120%) in 
the case of products like Oruvail for which there is high inter-subject and intra­
subject variation. While these statistical considerations are of both academic and 
regulatory interest, it seems clear that the 2-1STT is not appropriate for Oruvail 
studies and that 6E/5A/IND is equivalent to Oruvail in terms of AUC and C.. 90 
CONCLUSIONS
 
Area under the excretion rate - time curve for 6E/5A/IND is equivalent 
with Oruvail, and maximum excretion rate of ketoprofen is also equivalent. Time 
to maximum excretion rate for Oruvail is longer than for the test formulation, but 
this is not a critical parameter in the bioequivalence of controlled release products. 
Clinical trials conducted with 6E/5A/IND beads should lead to acceptance of 
bioequivalence with Oruvail. 
Urinary analysis of drug excretion for compounds that are extensively 
eliminated through the kidneys as intact drug or a metabolite is a valuable, non­
invasive, pharmacokinetic tool.  If each subject exhibits an invariant elimination 
rate constant for a drug and urinary clearance of the drug is dependant on input 
functions that in turn are dependent on release rates from test formulations, then 
the pharmacokinetics of a test formulation can be estimated by deconvolution of 
elimination data.  Thus, deconvolution of urinary excretion data provides a method 
of assessing effects of modifications in developmental drug formulations. Input 
functions from deconvolution of excretion rate data are easy to interpret for in vivo 
onset, rate, and extent of dissolution. 91 
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CHAPTER 4
 
IN VITRO - IN VIVO CORRELATIONS AND CONVOLUTION;
 
A PRACTICAL GUIDE
 
by Kris E. Holt and James W. Ayres 93 
ABSTRACT
 
Purpose: Practical guide for the establishment and use of an In Vitro - In Vivo 
Correlation (IVIVC) for development of bioequivalent formulations. 
Results: Factors affecting formulation dissolution and deconvolution of biostudy 
data towards establishment of an IVIVC are discussed while citing specific 
examples from a case study in the formulation of ketoprofen beads to be 
bioequivalent to Oruvail. Ultimate goal of IVIVC is to predict in vivo biostudy 
results from in vitro test formulation dissolution data. 
Conclusion: IVIVC is an accurate tool for predicting biostudy results from in 
vitro dissolution tests if proper considerations are made for: In vitro dissolution 
protocol parameters; In vivo biostudy data to be collected; and deconvolution 
method. An IVIVC is often biphasic rather than the expected linear relationship. 
This paper details methods to avoid formation of a biphasic IVIVC, and how to 
correct a previously established IVIVC that exhibits a non-linear relationship. 
INTRODUCTION 
Methods of establishing an IVIVC have been published(1,2), but an 
assumption seems to exist that establishment is relatively simple and 
straightforward. Without proper consideration of the factors that underlie an 
IVIVC, establishment may be either impossible or meaningless. 94 
The following is meant as a guideline for the formulation practitioner; i.e., 
one with a basic appreciation for pharmacokinetics but without extensive 
pharmacokinetic expertise. Each step in the establishment and use of an IVIVC is 
discussed. These suggestions are by no means exhaustive, but will suffice to 
anticipate many of the expected difficulties in establishing a meaningful IVIVC. 
RESULTS AND DISCUSSION 
Dissolution 
Proper choice of a dissolution protocol is based on the formulation and/or 
solubility of the drug incorporated in the formulation. The object of in vitro 
dissolution for correlations is to reproducibly generate a release curve which can 
be related to in vivo release. Prior in vivo experience with drug release from 
similar formulations or evidence from a preliminary biostudy will greatly aid in 
selection of a proper in vitro dissolution protocol. Enteric coated formulations or 
drugs with a low solubility in gastric fluid administered in a biostudy under fasting 
conditions may lead to a lag time of up to 2.7 hours(3) before onset of a measured 
in vivo response. In these cases, it is wise to include a gastric pretreatment phase 
into the dissolution protocol. Some beads administered in a capsule may also be 
retained in the stomach for up to 2 hours, but their size allows some beads to spill 
over through the pylorus in advance of the majority of the dose. Thus, enteric 
coating or low drug solubility will lead to a lag time between dose administration 
and measured response in vivo, but in vivo dissolution may not show a sharp 95 
demarcation between gastric and intestinal release. Note that enteric coated tablets 
and beads have an inherent difference in their release mechanisms due to full 
gastric retention of tablets and partial release of beads in advance of gastric 
emptying. 
Another consideration in development of an in vitro dissolution protocol is 
selection of equipment to be employed. USP dissolution apparati 1-3 are most 
commonly used for controlled release formulations. Apparatus 1, the basket 
method, is most commonly used for capsule formulations. A basket ensures total 
immersion of a capsule into the media, and aids in withdrawal of beads during 
fluid changeover. From a hydrodynamic standpoint, the basket method is probably 
the most gentle of the procedures listed.  Apparatus 2, the paddle method, is most 
commonly used for tablets, although it can also be employed for capsules. The 
amount of shear force exerted by the media on the formulation can be increased by 
increasing the rate of paddle revolution, but formulations tend to sit in the bottom 
center of the dissolution vessel where effects of paddle rotation are minimized. 
For matrix or erodible formulations, apparatus 3 is now commonly employed. The 
device consists of a reciprocating basket that should more closely mimics effects of 
tumbling and mechanical erosion imparted by transit through a GI tract.  In each 
case, it is a good idea to test the effect of rotation/reciprocation speed on rate of in 
vitro dissolution. 
Figure 4.01 shows dissolution profiles with 2 hours gastric acid 
pretreatment for model formulations of enteric coated controlled release 
ketoprofen.  Oruvail, a marketed product which contains enteric coated beads in a III
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Figure 4.01: Dissolution profiles for formulations of controlled release ketoprofen 97 
capsule, releases less than 2% total dose during a 2 hour gastric pre-treatment. 
Complete dissolution is achieved following an additional 12 hour intestinal fluid 
treatment. Test formulation 6E5A is also enteric coated beads in a capsule, and 
releases no detectable drug in a 2 hour gastric pretreatment. Dissolution of the 
formulation is nearly complete after an additional treatment of 6 hours in simulated 
intestinal fluid. Orudis SR-200 tablets, available in Canada and the United 
Kingdom, are an enteric-coated matrix tablet formulation. In vitro dissolution of 
Orudis shows no drug release during gastric pretreatment, and an additional 68 
hours of intestinal fluid treatment is required to achieve 100% dissolution. 
Biostudy Data 
Normally, plasma drug concentration (Cp) is monitored during a biostudy. 
Alternate choices for measurable input response parameters include urinary 
excretion rate of drug or metabolite(dUidt), blood or plasma metabolite 
concentration, blood pressure alteration, body temperature alteration, writhing, 
pulse rate alteration, blood clotting time; in short, any factor affected by absorption 
of a drug substance that has a measurable outcome and is linked to a circulating 
level of the drug in blood or tissue.  Input response can arise as a direct 
consequence of drug absorption, or as a response to circulating blood levels of 
drug by a secondary metabolic or enzymatic pathway. 
Measured input responses that arise from a threshold or triggering level of 
circulating drug may be very difficult to ultimately correlate to an in vitro 
dissolution pattern due to their lack of direct dependence on small changes for in 98 
vivo drug dissolution. Hourly fluctuations in drug dissolution rates from a 
formulation in the GI tract has little bearing on the rate or extent of input response 
measured in this case; only the time of activation/deactivation is affected. 
Biostudies of model formulations for this report monitored urinary excretion 
rate (dU/dt) of ketoprofen. Urinary excretion rate data are easy to gather and have 
advantages of using a non-invasive sampling procedure and being indicative of 
relative blood concentrations through first-order elimination processes. Biostudies 
of subjects ingesting immediate release capsules were conducted to obtain an 
average elimination rate constant to be used as the impulse response for 
deconvolution of controlled release formulation biostudy data. Biostudies were 
conducted on fasted subjects in a non-crossover fashion. A standardized breakfast 
was provided to subjects following collection of two hours of urine production. 
Figure 4.02 shows the average urinary excretion rate of ketoprofen for fasted 
subjects ingesting the 200mg controlled release (CR) formulations shown in figure 
4.01. Excretion rate maxima are about the same for all three CR formulations but 
the area under the Orudis curve (AUC = 161) is visibly larger than those of 
Oruvail (AUC = 115) and the test formulation (AUC = 113). Orudis SR-200 
tablets are clearly retained in the empty stomach longer than the bead formulations 
as evidenced by a marked 2 hour lag prior to ketoprofen excretion. This is in 
direct agreement with the dissolution data, but the bead formulations released drug 
in vivo in less than two hours. This time difference is evidence that some beads 
were not retained in the stomach and began drug release in advance of the majority 
of the dose administered. 14 
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Figure 4.02: Average urinary excretion rate of ketoprofen for fasted subjects ingesting immediate and controlled release formulations 100 
Assay Protocol 
Deconvolution will determine the time-course of drug input into circulation 
to balance the amount of analyte detected. With detection of parent drug in 
circulation (blood or plasma), deconvolved input functions are subject only to 
bioavailability as to the amount of maximum cumulative input. Input functions 
deconvolved from the assay of other analytes, especially metabolites of parent 
drug, are subject to other limitations enumerated in the deconvolution section. An 
assay procedure, usually HPLC, must be accurate and reproducible, and reflect 
sample degradation where appropriate in order to generate data that is a good 
representation of response to drug input. Response is usually the measured drug 
time course. 
Under ideal conditions, standards for analyte quantitation are prepared in 
biological fluid blanks and are treated as samples; undergoing all sample 
preparation procedures such that they are truly representative of the sample 
concentration range. Preparative procedures can include storage conditions, where 
appropriate, if there is to be an expected lag between sampling time and 
concentration analysis. 
Assay procedures for this study are extensively enumerated elsewhere(4). 
Urine samples, after spiking with internal standard, were subjected to base 
hydrolysis to convert metabolites into parent drug and extracted to remove 
competing urine chromophores. After acidification, extraction, and drying, 
reconstituted samples were analyzed by HPLC against known concentrations of 
ketoprofen in blank urine that had been similarly spiked, hydrolyzed, and 101 
extracted. Note that the hydrolysis step is required to convert ketoprofen 
glucuronides to parent drug so that all excreted drug was assayed. Peak height 
ratio between ketoprofen and internal standard was found to be linear from 0/4/m1 
to over 700/4/ml. 
Selection of Impulse Response Function 
Impulse response is the term used in deconvolution(5) to describe the 
relationship of incremental drug input relative to the observed level of input 
response measured in a biostudy. Impulse response has units of (input response 
units) divided by (drug input units) and is used in a deconvolution program to 
determine in vivo dissolution from biostudy data. Under ideal conditions, impulse 
response is derived from the terminal slope of log-transformed input response data 
following administration of an IV bolus dose of drug. In absence of IV data, an 
oral administration of immediate release drug can provide the elimination rate 
constant needed. Useful values for impulse response can also be derived from 
literature, provided that the desired input response has been followed in a previous 
biostudy, or can be estimated from existing data using a body of assumptions. 
Under an assumption of bioequivalence in a biostudy to test for bioequivalence, 
selection of an impulse response function can be arbitrary provided that data from 
both test and reference formulations are treated identically. Use of an arbitrary 
value for impulse response is valid because of assumed bioequivalence; if 
bioequivalence is true, then in vivo drug dissolution and elimination are also 
bioequivalent. 102 
In this study, urinary excretion rate of ketoprofen was monitored. The 
decay function, determined following oral IR dose administration, is the rate in 
which the urinary excretion rate of ketoprofen decreases. Impulse response for 
this system is therefore the deceleration factor for urinary excretion of ketoprofen. 
Figure 4.03 shows the natural log transformed average urinary ketoprofen 
excretion rate resulting from administration of a 75mg IR dose under fasting 
conditions. 
Deconvolution 
Deconvolution software used in this report was PCDCON by William 
Gillespie, although many others are now available. Deconvolution generates an 
input function from biostudy data (input response) of a controlled or sustained 
release formulation and its characteristic impulse response function. An input 
function is cumulative amount of drug absorbed versus time; the integral of 
absorption rate. Under an assumption that absorption is much faster than in vivo 
dissolution, the input function is also the in vivo dissolution curve. 
If the analyte assayed during a biostudy is a drug metabolite, deconvolution 
may only reveal the biotransformation process; especially if the process is saturable 
and the input response is a function of metabolite concentration. A plot of 
metabolite concentration versus effect (input response) would not show a hysteresis 
loop, as with the same plot of parent drug concentration. Consider a two 
compartment model in which drug elimination is through a capacity-limited 
biotransformation that constitutes the second compartment. N
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If metabolite is assayed in a biostudy, either in urine or plasma, metabolite 
concentration is not indicative of circulating parent drug blood concentration when 
saturation of the biotransformation process is achieved at any time post-dose. A 
deconvolved input function from this system will reveal cumulative amount of drug 
that has undergone biotransformation and will exhibit a linear slope without log 
transformation for the time during which plasma concentration of parent drug 
exceeds the limits of the saturable transformation process. Information from this 
system can be quite useful for pharmacoldnetic or pharmacodynamic modeling, but 
it will not reveal in vivo dissolution rates of the formulation under examination. In 
combination with an assay for the circulating concentration of parent drug, 
however, the complete picture of absorption, metabolism and elimination can be 
revealed. 
Figure 4.04 shows the input functions deconvolved from biostudy data for 
controlled release ketoprofen formulations. Ketoprofen release rates of two of the 
formulations are quite similar, and nearly identical after 10 hours. The faster 
release rate of ketoprofen from 6E5A 1-5 hours post dose is reflected in the earlier 
maximum urinary excretion rate shown in figure 4.02. Similarity between the two 
release rates was established with statistical testing of biostudy data proving 
bioequivalence by the two-1 sided T tests.  Release rate of ketoprofen from Orudis 
is initially fast, but becomes nearly constant within 5 hours post dose.This figure 
clearly illustrates that the mechanism of release from a compressed matrix tablet is 
different from that of a coated bead formulation. 125 
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Figure 4.04: Deconvolved input functions from biostudy data for controlled  release ketoprofen formulations 106 
In Vitro/In Vivo Correlation (IVIVC) 
Correlations are developed by plotting in vitro dissolution (X axis) versus 
deconvolved in vivo dissolution (input function, Y axis) along an identical, but 
=shown, third time axis. Now comes the art of correlation.  Ideally, times of 
maximum dissolution are approximately equal, both in vitro and in vivo. The 
resulting IVIVC is a relatively simple curve. If the times of maximum dissolution 
are not equal, the IVIVC curve will appear to be biphasic. The correlation curve 
will approach 100% completion along one axis, usually in vitro, then approach 
100% completion on the second axis.  If the IVIVC curve appears to be composed 
of 2 relatively linear sections having different slopes, then the in vitro dissolution 
results must be scaled so that time of maximum dissolution is similar to that of 
time of maximum deconvolved input. 
In vitro and in vivo data sets are then interpolated so the time scale occurs 
in equal and common increments over a desired range. In this study, dissolution 
data were interpolated to half-hour increments over a range of 0-25 hours. 
Interpolated data are then plotted with in vitro dissolution as the X axis and in vivo 
dissolution as the Y axis.  If the time scale for in vitro dissolution was altered, the 
factor is recorded in the legend. 
Figure 4.05 shows the uncorrected correlations for controlled release 
ketoprofen formulations. Note the nearly vertical slopes, especially for 6E5A, 
when in vitro release is nearing completion but in vivo release still occurs at a 
fairly steady rate. 50  100  150
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Figure 4.05: IVIVC's for controlled release ketoprofen formulations 
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Figure 4.06 shows the same data corrected by scaling so that maximum in vitro 
dissolution occurs at 25 hours by multiplying in vitro dissolution time by a scaling 
factor of 25/(maximum dissolution time) prior to interpolation to half-hour 
intervals for plotting an IVIVC. In vivo drug dissolution is unacceptably high in 
the trace for 6E5A due to the scaling of both gastric fluid and intestinal fluid 
dissolution times; scaled gastric time was 2*(25/8) = 6.25 hours by which time 
nearly 50% of the recovered dose had been excreted.  Similarly, in vivo drug 
dissolution is unacceptably low in the trace for Orudis SR-200 due to the scaling of 
both gastric fluid and intestinal fluid dissolution times; scaled gastric time was 
2*(25/68) = 0.74 hours followed by rapid initial release. Under the new time 
scale, in vitro dissolution was 25% complete before in vivo absorption occurs. To 
eliminate this effect, intestinal fluid dissolution time alone for 6E5A was corrected 
by scaling the 6 hour duration to 23 hours and interpolating to half-hour intervals. 
Adding the original 2 hour gastric dissolution gives a 25 hour corrected dissolution 
that yields a much more acceptable IVIVC shown in figure 4.07. Similarly, 
intestinal fluid dissolution time alone for Orudis SR-200 was corrected by scaling 
the 68 hour duration to 23 hours and interpolating to half-hour intervals. Adding 
the original 2 hour gastric dissolution gives a 25 hour corrected dissolution that 
yields a much more acceptable IVIVC shown in figure 4.07. ,t70 140 
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Figure 4.06: Dissolution time-scaled IVIVC's for controlled release ketoprofen formulations q,z 140 
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Figure 4.07: Dissolution time-scaled IVIVC's for controlled release ketoprofen formulations; effect of scaling intestinal 
fluid dissolution time 111 
Convolution Of Additional In Vitm Data 
When an AVIV correlation has been developed, in vitro dissolution data 
from a modified formulation can be used to predict in vivo input response to the 
new formulation. Correlations developed as above can be used with confidence to 
predict in vivo response to formulation changes. Formulation changes that affect 
the mechanism of drug release make predictions based on developed correlations 
suspect. This is apparent from previous discussion of IVIVC for Oruvail and 
6E5A beads versus Orudis SR-200 compressed tablets; different control 
mechanisms are involved. 
Using a developed correlation, in vitro dissolution data from a modified 
formulation are converted to an in vivo input function. If the correlation was 
developed from time-compressed/expanded in vitro data, the dissolution data to be 
input into the correlation must be altered in a similar manner. Following 
conversion, the predicted input function is interpolated to a uniform time scale and 
the difference in cumulative input between consecutive time points is calculated for 
convolution; convolution is based on the effects of incremental, not cumulative, 
input. This process is more easily explained graphically, as follows. 
Convolution is the summation of effects, through superposition, from an 
input and the remaining portions of previous inputs. The outcome of convolution 
is shown graphically in figure 4.08. Each incremental input is subjected to an 
impulse response, the characteristic decay function for a measured input response. Urinary Excretion: c(t) 
Drug Input: f(t) 
e
4,
0 
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Time of Input (hours)  14  Time of Excretion (hours) 
Characteristic Elimination Functions: c6(t) 
Figure 4.08: Graphical representation of convolution 113 
In effect, each incremental input is treated as an IV bolus dose of drug that is 
injected at the beginning of the time increment (each half hour for this paper). The 
convolved curve, a prediction of in vivo response, results from the summation of 
the remaining effects of all prior incremental inputs at the beginning of each time 
increment. Rotation of the axes reveal incremental inputs of the input function in 
one direction (figure 4.09) and individual contributions of the remaining effects of 
each input to response through superposition (figure 4.10) in the other. The plane 
formed by those two axes is time  in which impulse response acts upon each 
incremental input. 14 
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7  14 
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Figure 4.09: Incremental drug input from the input function 
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Figure 4.10: Superposition of input responses arising from inciciuental inputs 116 
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